

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Filed In Triplicate  
1 of 3


### Appeal Brief

Applicant(s)	Turner et al.
Application #	09/691,343
Date Filed	Oct 18, 2000
Title	Novel Human Proteins and Polynucleotides Encoding the Same
Attorney Docket #	LEX-0070-USA
Group Art Unit	1647
Examiner	R. DeBerry



## TABLE OF CONTENTS

I.	REAL PARTY IN INTEREST .....	1
II.	RELATED APPEALS AND INTERFERENCES .....	1
III.	STATUS OF THE CLAIMS .....	2-3
IV.	STATUS OF THE AMENDMENTS .....	3
V.	SUMMARY OF THE INVENTION .....	3-4
VI.	ISSUES ON APPEAL .....	4
VII.	GROUPING OF THE CLAIMS .....	4
VIII.	ARGUMENT .....	4-27
	A. Do Claims 4-11 Lack a Patentable Utility? .....	4-19
	B. Are Claims 4-11 Unusable Due to a Lack of Patentable Utility? .....	19
	C. Are Claims 4, 7 and 8 Enabled? .....	19-24
	D. Does Claim 4 Meet The Written Description Requirement? .....	24-27
IX.	APPENDIX .....	28
X.	CONCLUSION .....	29



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Turner Jr. *et al.*

Serial No.: 09/691,343

Group Art Unit: 1647

Filed: 10/18/2000

Examiner: R. DeBerry

For: Novel Human Proteins and Polynucleotides Encoding the Same Attorney Docket No.: LEX-0070-USA

**APPEAL BRIEF**

**Mail Stop Appeal Brief - Patents**  
Assistant Commissioner for Patents  
Alexandria, VA 22313

02/26/2004 AWONDAF1 00000117 09691343

01 FC:2402 165.00 DA

## **APPEAL BRIEF**

Sir:

Appellants hereby submit an original and two copies of this Appeal Brief to the Board of Patent Appeals and Interferences ("the Board") in response to the Final Office Action mailed on June 16, 2003. The Notice of Appeal was timely submitted on October 16, 2003, and was received in the Patent and Trademark Office ("the Office") on October 20, 2003. This Appeal Brief is timely submitted in light of the concurrently filed Petition for an Extension of Time of two months to and including February 20, 2004, and authorization to deduct the fee as required under 37 C.F.R. § 1.17(a)(2) from Appellants' Representatives' deposit account. The Commissioner is also authorized to charge the fee for filing this Appeal Brief (\$165.00), as required under 37 C.F.R. § 1.17(c), to Lexicon Genetics Incorporated Deposit Account No. 50-0892.

Appellants believe no fees in addition to the fee for filing the Appeal Brief and the fee for the extension of time are due in connection with this Appeal Brief. However, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason related to this communication, the Commissioner is authorized to charge any underpayment or credit any overpayment to Lexicon Genetics Incorporated Deposit Account No. 50-0892.

### **I. REAL PARTY IN INTEREST**

The real party in interest is the Assignee, Lexicon Genetics Incorporated, 8800 Technology Forest Place, The Woodlands, Texas, 77381.

### **II. RELATED APPEALS AND INTERFERENCES**

Appellants know of no related appeals or interferences that will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

### **III. STATUS OF THE CLAIMS**

The present application was filed on October 18, 2000, claiming the benefit of U.S. Provisional Application Numbers 60/160,106 and 60/162,547, which were filed on October 18, 1999

and October 29, 1999, respectively, and included original claims 1-6. A Restriction and Election Requirement was issued on July 22, 2002, separating the original claims into three separate and distinct inventions. In a response to the Restriction and Election Requirement submitted to the Office on August 22, 2002, Appellants elected without traverse the claims of the Group III invention (original claims 4-6) for prosecution on the merits, cancelled claims 1-3 without prejudice and without disclaimer as drawn to non-elected inventions, amended claim 5 to further improve its clarity, and added new claims 7 and 8.

A First Official Action on the merits (“the First Action”) was issued on November 6, 2002, in which claims 4-8 were rejected under 35 U.S.C. § 101 as allegedly lacking a patentable utility, claims 4-8 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly unusable by the skilled artisan due to the alleged lack of patentable utility, claims 4, 7 and 8 were apparently rejected under 35 U.S.C. § 112, first paragraph, as allegedly not providing enablement for “fragments of polynucleotides” (the First Action at page 6), claims 4 and 5 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention, and claim 5 was rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite. In a response to the First Action submitted to the Office on March 6, 2003 (“Response to the First Action”), Appellants amended claim 5 to even further improve its clarity, added new claims 9-11, and addressed the various rejections of claims 4-8.

A Second and Final Official Action (“the Final Action”) was issued on June 16, 2003, indicating that the rejection of claim 5 under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention, and claim 2 under 35 U.S.C. § 112, second paragraph, as allegedly indefinite, had been overcome by the amendments and remarks submitted in the Response to the First Action, but maintaining the rejection of claims 4-8 (and newly added claims 9-11) under 35 U.S.C. § 101 as allegedly lacking a patentable utility, claims 4-8 (and newly added claims 9-11) under 35 U.S.C. § 112, first paragraph, as allegedly unusable by the skilled artisan due to the alleged

lack of patentable utility, claims 4, 7 and 8 under 35 U.S.C. § 112, first paragraph, as allegedly not enabled, and claim 4 under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. In a response to the Final Action submitted to the Office on October 16, 2003 (“Response to the Final Action”), Appellants addressed the various rejections of claims 4-11.

An Advisory Action (“the Advisory Action”) was mailed on December 17, 2003, maintaining the rejection of claims 4-11 under 35 U.S.C. § 101 as allegedly lacking a patentable utility, claims 4-11 under 35 U.S.C. § 112, first paragraph, as allegedly unusable by the skilled artisan due to the alleged lack of patentable utility, claims 4, 7 and 8 under 35 U.S.C. § 112, first paragraph, as allegedly not enabled, and claim 4 under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Therefore, claims 4-11 are the subject of this appeal. A copy of the appealed claims are included below in the Appendix (Section IX).

#### **IV. STATUS OF THE AMENDMENTS**

As no amendments subsequent to the Final Action have been filed, Appellants believe that no outstanding amendments exist.

#### **V. SUMMARY OF THE INVENTION**

The present invention relates to Appellants’ discovery and identification of novel human polynucleotide sequences that encode a novel member of the platelet-derived growth factor/VEGF family (specification from page 2, line 34 to page 3, line 1).

The presently claimed polynucleotide sequences were compiled from clustered human gene trapped sequences and ESTs (specification at page 7, lines 29-30). A coding single nucleotide polymorphism was identified in the claimed sequence - specifically, an A/T polymorphism at position 598 of SEQ ID NO:6, which can lead to an isoleucine or valine residue at amino acid position 200 of SEQ ID NO:7 (specification from page 7, line 37 to page 8, line 2).

The specification details a number of uses for the presently claimed polynucleotide sequences, including in diagnostic assays such as forensic analysis (see, for example, the specification at page 10, line 35), in determining the genomic structure (see, for example, the specification at page 3, lines 9-13), and in assessing gene expression patterns, particularly using a high throughput “chip” format (see, for example, page 5, lines 4-7, in priority document 60/162,547, which was incorporated in its entirety by reference into the present specification as originally filed).

## **VI. ISSUES ON APPEAL**

1. Do claims 4-11 lack a patentable utility?
2. Are claims 4-11 unusable by a skilled artisan due to a lack of patentable utility?
3. Are claims 4, 7 and 8 enabled?
4. Does claim 4 lack sufficient written description?

## **VII. GROUPING OF THE CLAIMS**

For the purposes of the outstanding rejections under 35 U.S.C. § 101 and 35 U.S.C. § 112, first paragraph, associated with the utility rejection, the claims will stand or fall together. For the purpose of the outstanding rejection under 35 U.S.C. § 112, first paragraph, associated with enablement, claims 4, 7 and 8 will stand or fall together. For the purpose of the outstanding rejection under 35 U.S.C. § 112, first paragraph, associated with written description, claim 4 will stand or fall alone.

## **VIII. ARGUMENT**

### **A. Do Claims 4-11 Lack a Patentable Utility?**

The Final Action first rejects claims 4-11 under 35 U.S.C. § 101, as allegedly lacking a patentable utility due to not being supported by either a specific and substantial or a well-established utility.

Appellants pointed out both in the Response to the First Action and the Response to the Final Action that the present nucleic acid sequences clearly have utility in diagnostic assays such as forensic analysis, as described in the specification as originally filed (see, for example, page 10,



line 35). As described in the specification from page 7, line 37 to page 8, line 2, the presently claimed sequence defines a coding single nucleotide polymorphisms - specifically, an A/T polymorphism at position 598 of SEQ ID NO:6, which can lead to an isoleucine or valine residue at amino acid position 200 of SEQ ID NO:7. As polymorphisms such as this are the basis for forensic analysis, which in undoubtedly a “real world” utility, the presently claimed sequence must in itself be useful.

In the Final Action, the Examiner questioned this asserted utility, stating “it does not mean that the change in amino acid will affect activity or cause a disease or condition” (the Final Action at page 3). The Examiner reiterates this position in the Advisory Action, stating that “(a) way of identifying a population of people which (*sic*) carry a particular polymorphism, wherein the polymorphism itself does not cause a disease or condition (i.e. (*sic*) lacks a substantial utility) fails to have a ‘real world use’” (the Advisory Action at page 2). Naturally occurring genetic polymorphisms such as that described in the present specification are both the basis of, and critical to, *inter alia*, forensic genetic analysis intended to resolve issues of, for example, identity or paternity. Forensic analysis based on identified polymorphisms such as that identified by Appellants is used to positively identify or rule out suspects in many criminal cases, and in identifying human remains. Paternity determination is based on identified polymorphisms such as that identified by Appellants to positively identify or rule out individuals suspected of fathering a particular child. Therefore, Appellants find the Examiner’s position particularly difficult to comprehend. What could be possibly be more substantial and real world than the loss of an individual’s freedom or life through incarceration? What could be possibly be more substantial and real world than the positive identification of human remains? What could be possibly be more substantial and real world than the impact, both economic and emotional, that the results of a paternity analysis has on the individuals directly and indirectly involved? These are all well known and generally accepted uses of identified polymorphisms such as the polymorphism identified by Appellants. Without such identified polymorphisms, the skilled artisan would not be able to carry out such forensic or paternal analyses. Thus, the Examiner’s argument in no way supports the allegation that the presently claimed sequence lacks a patentable utility.

**Far** from supporting the allegation that the presently claimed sequence lacks a patentable

utility, these arguments instead merely reflect how **completely** misinformed the Examiner is with **forensic** analysis. Appellants respectfully pointed out in the Response to the Final Action that **forensic** analysis is used to specifically identify individual members of the human population based simply on the **presence** or **absence** of one or more polymorphisms. Appellants reiterate that **forensic** analysis does not require **any information at all** about the ultimate biological function of the encoded protein, or require that the mutation cause a “disease or condition”. Using the polymorphic marker as described in the specification as originally filed, the skilled artisan can distinguish members of a population from one another without **any** additional research. In the **worst case** scenario, this polymorphic marker is useful to distinguish 50% of the population (in other words, the marker being present in half of the population). Appellants point out that the ability of a polymorphic marker to distinguish **at least** 50% of the population is an inherent feature of any polymorphic marker, and this feature is well understood by those of skill in the art. Appellants note that as a matter of law, it is well settled that a patent need not disclose what is well known in the art. *In re Wands*, 8 USPQ 2d 1400 (Fed. Cir. 1988). Appellants respectfully point out that all that is required to support this assertion of utility is for the skilled artisan to believe that the presently described polymorphic marker could be useful in forensic analysis. The fact that forensic biologists use polymorphic markers such as that described by Appellants **every day** provides more than ample support for the assertion that forensic biologists would also be able to use the specific polymorphic marker described by Appellants in the same fashion. Therefore, the presently claimed sequence clearly has a substantial and well established utility. The ability to eliminate 50% of the population from a forensic analysis **clearly** is a real world, practical utility.

Furthermore, Appellants submit that the asserted forensic utility is specific precisely because it **cannot** be applied to just **any** polynucleotide. In fact, the basis for forensic analysis is the fact that such polymorphic markers are **not** present in **all** other nucleic acids, but in fact **specific** and **unique** to only a certain subset of the population. Additionally, until a polymorphic marker is actually described it cannot be used in forensic analysis. Put another way, simply because there is a likelihood, even a significant likelihood, that a particular nucleic acid sequence will contain a polymorphism and thus be useful in forensic analysis, until such a polymorphism is actually identified and described, such a likelihood is **meaningless**. Additionally, as set forth in the Response

to the First Action and the Response to the Final Action, the requirement for a specific utility, which is the proper standard for utility under 35 U.S.C. § 101, should not be confused with the requirement for a unique utility, which is clearly an improper standard. As clearly stated by the Federal Circuit in *Carl Zeiss Stiftung v. Renishaw PLC*, 20 USPQ2d 1101 (Fed. Cir. 1991; “*Carl Zeiss*”):

An invention need not be the best or only way to accomplish a certain result, and it need only be useful to some extent and in certain applications: “[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding a lack of utility.” *Envirotech Corp. v. Al George, Inc.*, 221 USPQ 473, 480 (Fed. Cir. 1984)

In other words, just because other (possibly better) polymorphic markers from the human genome have been described, or that additional information about the presently described polymorphic markers can be gained through the use of these markers, does not establish that the presently described polymorphic markers lack a specific utility. Furthermore, the requirement for a unique utility is clearly not the standard adopted by the Patent and Trademark Office. If every invention were required to have a unique utility, the Patent and Trademark Office would no longer be issuing patents on batteries, automobile tires, golf balls, golf clubs, and treatments for a variety of human diseases, such as cancer, just to name a few particular examples, because the utility of each of these compositions is applicable to the broad class in which each of these compositions falls: all batteries have the same utility, specifically to provide electrical power; all automobile tires have the same utility, specifically for use on automobiles; all golf balls and golf clubs have the same utility, specifically for use in the game of golf; and all cancer treatments have the same utility, specifically, to treat cancer. However, only the briefest perusal of virtually any issue of the Official Gazette provides numerous examples of patents being granted on each of the above compositions nearly every week. Furthermore, if a composition needed to be unique to be patented, the entire class and subclass system would be an effort in futility, as the class and subclass system serves solely to group such common inventions, which would not be required if each invention needed to have a unique utility. In view of the above standards and “common sense” analysis, there can be little question that the present sequence clearly meets the requirements of 35 U.S.C. § 101.

Furthermore, as the presently described polymorphism is a part of the family of polymorphisms that have a well established utility, the Federal Circuit’s holding in *In re Brana*,

(34 USPQ2d 1436 (Fed. Cir. 1995), “*Brana*”) is directly on point. In *Brana*, the Federal Circuit admonished the Patent and Trademark Office for confusing “the requirements under the law for obtaining a patent with the requirements for obtaining government approval to market a particular drug for human consumption”. *Brana* at 1442. The Federal Circuit went on to state:

At issue in this case is an important question of the legal constraints on patent office examination practice and policy. The question is, with regard to pharmaceutical inventions, what must the applicant provide regarding the practical utility or usefulness of the invention for which patent protection is sought. This is not a new issue; it is one which we would have thought had been settled by case law years ago.

*Brana* at 1439, emphasis added. The choice of the phrase “utility or usefulness” in the foregoing quotation is highly pertinent. The Federal Circuit is evidently using “utility” to refer to rejections under 35 U.S.C. § 101, and is using “usefulness” to refer to rejections under 35 U.S.C. § 112, first paragraph. This is made evident in the continuing text in *Brana*, which explains the correlation between 35 U.S.C. §§ 101 and 112, first paragraph. The Federal Circuit concluded:

FDA approval, however, is not a prerequisite for finding a compound useful within the meaning of the patent laws. Usefulness in patent law, and in particular in the context of pharmaceutical inventions, necessarily includes the expectation of further research and development. The stage at which an invention in this field becomes useful is well before it is ready to be administered to humans. Were we to require Phase II testing in order to prove utility, the associated costs would prevent many companies from obtaining patent protection on promising new inventions, thereby eliminating an incentive to pursue, through research and development, potential cures in many crucial areas such as the treatment of cancer.

*Brana* at 1442-1443, citations omitted, emphasis added. As set forth above, the present polymorphism is useful in forensic analysis as described in the specification as originally filed, without the need for any further research. As discussed above, even if the use of this polymorphic marker provided additional information on the percentage of particular subpopulations that contain this polymorphic marker, this would not mean that “additional research” is needed in order for this marker as it is presently described in the instant specification to be of use to forensic science. As stated above, using the polymorphic marker as described in the specification as originally filed can definitely distinguish members of a population from one another. However, even if, *arguendo*, further research might be required in certain aspects of the present invention, this does not preclude a finding that the invention has utility, as set forth by the Federal Circuit’s holding in *Brana*, which

clearly states, as highlighted in the quote above, that “pharmaceutical inventions, necessarily includes the expectation of further research and development” (*Brana* at 1442-1443, emphasis added). In assessing the question of whether undue experimentation would be required in order to practice the claimed invention, the key term is “undue”, not “experimentation”. *In re Angstadt and Griffin*, 190 USPQ 214 (CCPA 1976). The need for some experimentation does not render the claimed invention unpatentable. Indeed, a considerable amount of experimentation may be permissible if such experimentation is routinely practiced in the art. *In re Angstadt and Griffin, supra*; *Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.*, 18 USPQ2d 1016 (Fed. Cir. 1991). Again, as a matter of law, it is well settled that a patent need not disclose what is well known in the art (*In re Wands, supra*).

Importantly, it has been clearly established that a statement of utility in a specification must be accepted absent reasons why one skilled in the art would have reason to doubt the objective truth of such statement. *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA, 1974; “*Langer*”); *In re Marzocchi*, 439 F.2d 220, 224, 169 USPQ 367, 370 (CCPA, 1971). As set forth in *In re Langer* (183 USPQ 288 (CCPA 1974); “*Langer*”):

As a matter of Patent Office practice, a specification which contains a disclosure of utility which corresponds in scope to the subject matter sought to be patented must be taken as sufficient to satisfy the utility requirement of § 101 for the entire claimed subject matter unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope.

*Langer* at 297, emphasis in original. As set forth in the MPEP, “Office personnel must provide evidence sufficient to show that the statement of asserted utility would be considered ‘false’ by a person of ordinary skill in the art” (MPEP, Eighth Edition at 2100-40, emphasis added). Thus, absent such evidence from the Examiner concerning the use of the presently described polymorphism in forensic analysis, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Additionally, Appellants pointed out in both the Response to the First Action and the Response to the Final Action that Appellants’ assertion in the specification as originally filed that the presently claimed sequence encodes a member of the platelet derived growth factor (PDGF) family (see the specification as originally filed, at least from page 2, line 34 to page 3, line 1) is supported by the fact that four sequences sharing 100% percent identity at the protein level over an

extended region of the claimed sequence are present in the leading scientific repository for biological sequence data (GenBank), and have been annotated by third party scientists who are *wholly unaffiliated with Appellants* as “Homo sapiens platelet derived growth factor C” (Li *et al.*, *Nat. Cell Biol.* 2:302-309, 2000 and Gilbertson *et al.*, *J. Biol. Chem.* 276:27406-27414, 2001; GenBank accession numbers NM\_016205 and AF260738, respectively; copies of the abstracts, alignments and GenBank reports that were provided with the Response to the First Action and the Response to the Final Action are provided in **Exhibit A**), “Homo sapiens secretory growth factor-like protein fallotein” (which is a member of the PDGF family; Tsai *et al.*, *Biochim. Biophys. Acta* 1492:196-202, 2000; copies of the abstract, alignment and GenBank report that were provided with the Response to the First Action and the Response to the Final Action are provided in **Exhibit B**), and “Homo sapiens hSCDGF mRNA for spinal-cord-derived growth factor (which is also a member of the PDGF family; Hamada *et al.*, *FEBS Lett.* 475:97-102, 2000; copies of the abstract, alignment and GenBank report that were provided with the Response to the First Action and the Response to the Final Action are provided in **Exhibit C**). Appellants respectfully pointed out that the legal test for utility simply involves an assessment of whether those skilled in the art would find any of the utilities described for the invention to be credible or believable. Given all of these GenBank annotations and scientific manuscripts, there can be no question that those skilled in the art would clearly believe that Appellants’ sequence is a member of the platelet derived growth factor family. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

In the Final Action, the Examiner questioned this assertion of utility, stating that “the polypeptide taught by the specification will not have activity as taught by Li *et al.*” (The Final Action bridging pages 4 and 5). Appellants pointed out in the Response to the Final Action that this argument is not particularly germane to Appellants’ assertion, since the alignments in **Exhibits A, B and C**, above, were provided to illustrate the extensive homology between the presently claimed sequence and a variety of members of the platelet derived growth factor family, not to show identity to any one specific members of the platelet derived growth factor family. Thus, while Appellants have provided evidence of record that conclusively establishes that those skilled in the art would believe that the specifically claimed sequence encodes a member of the platelet derived growth factor family, the Examiner has provided no evidence that directly establishes that the specifically claimed

sequence does not encode a member of the platelet derived growth factor family. Accordingly, the evidence of record compels a finding that the present invention has a patentable utility.

In the First Action, the Examiner cited an article by Skolnick *et al.* (*Trends in Biotech.* 18:34-39, 2000; “Skolnick”), an issued U.S. Patent to Tischer *et al.* (U.S. Patent No. 5,194,596; “Tischer”), and an article by Yan *et al.* (*Science* 290:523-527, 2000; “Yan”) to support the alleged lack of utility based upon protein homology such as that shown by Appellants above. Skolnick is cited for the proposition that “(k)nowing the protein structure by itself is insufficient to annotate a number of functional classes and is also insufficient for annotating the specific details of protein function” (the First Action at page 4, quoting Skolnick at page 36; emphasis added). However, Skolnick concerns predicting protein function not by overall amino acid homology to other family members, but instead concerns prediction of function based on the presence of certain functional “motifs” present within a given protein sequence. Thus, Skolnick does not apply to the current situation, where overall protein homology is used to assign function to a particular sequence. However, even in the event that Skolnick is applicable, Skolnick itself concludes that “sequence-based approaches to protein-function prediction have proved to be very useful” (Skolnick at page 37), admitting that such methods have correctly assigned function in 50-70% of the cases. Thus, Skolnick does not support the Examiner’s allegation that the presently claimed sequence lacks a patentable utility.

Tischer is cited for the proposition that individual members of a protein family can “have distinct, and sometimes even opposite, biological activities” (the First Action at page 4). While this may in fact be the case, an unusual case such as this, particularly one disclosed in a patent based on an application filed in 1989, ten years before the filing of the present application, hardly represents the view of those skilled in the art at the time of the present application regarding prediction of protein function based on homology. Appellants submit that, as described above, those skilled in the art in 1999 would clearly believe that Appellants’ sequence is a platelet derived growth factor.

Regarding Yan, only one example is cited in Yan, specifically, two isoforms of the anhidrotic ectodermal dysplasia (EDA) gene, where a two amino acid change conforms one isoform (EDA-A1) into the second isoform (EDA-A2). However, while it is true that this amino acid change results in binding to different receptors, it is important to note that the different receptors bound by the two isoforms are in fact related (Yan at page 523). Furthermore, the EDA-A2 receptor was correctly

identified as a member of the tumor necrosis factor receptor superfamily based solely on sequence similarity (Yan at page 523). Thus, Yan does not suggest a high level of uncertainty in assigning function based on sequence, and thus also does not support the alleged lack of utility.

Furthermore, with regard to the citation of journal articles to support an allegation of a lack of utility, the PTO has repeatedly attempted to deny the utility of nucleic acid sequences based on a small number of publications that call into doubt prediction of protein function from homology information and the usefulness of bioinformatic predictions, of which these articles are merely the latest examples. Appellants readily agree that there is not 100% consensus within the scientific community regarding prediction of protein function from homology information, and further agree that prediction of protein function from homology information is not 100% accurate. However, Appellants respectfully point out that the lack of 100% consensus on prediction of protein function from homology information is completely irrelevant to the question of whether the claimed nucleic acid sequence has a substantial and specific utility, and that 100% accuracy of prediction of protein function from homology information is not the standard for patentability under 35 U.S.C. § 101. Appellants respectfully point out that, as discussed above, the legal test for utility simply involves an assessment of whether those skilled in the art would find any of the utilities described for the invention to be believable. Appellants submit that the overwhelming majority of those of skill in the relevant art would believe prediction of protein function from homology information and the usefulness of bioinformatic predictions to be powerful and useful tools, as evidenced by hundreds if not thousands of journal articles (which Appellants will submit to the Office if the Board truly doubts Appellants' assertion that the overwhelming majority of those of skill in the art place a high value on prediction of protein function from homology information and the usefulness of bioinformatic predictions), and would thus believe that Appellants sequence is a member of the platelet derived growth factor family. As believability is the standard for meeting the utility requirement of 35 U.S.C. § 101, and not 100% consensus or 100% accuracy, Appellants submit that the present claims must clearly meet the requirements of 35 U.S.C. § 101.

Furthermore, the PTO itself does not require 100% identity between proteins to establish functional homology. Example 10 of the PTO's Revised Interim Utility Guidelines Training Materials only requires a similarity score greater than 95% to establish functional homology. Thus,



scientific publications that generally assert that very small changes between amino acid sequences can lead to changes in function, or publications describing specific examples of proteins, distinct from Appellants sequence, where a minor change in amino acid sequence has lead to a change in function, have been viewed by the **PTO itself** as irrelevant to the question of utility, and thus do not support the Examiner's allegation that the presently claimed sequence lacks utility. Therefore, the present utility rejection must fail as a matter of policy, as a matter of science, and as a matter of law.

In the Advisory Action, the Examiner continues to question Appellants' assertion of utility, stating "that the utility of a claimed DNA does not necessarily depend on the function of the encoded gene product, if the claimed DNA had a specific and substantial utility such as it hybridizes near a disease-associated gene or it has gene regulating activity" (the Advisory Action at page 2). Appellants respectfully point out that evidence showing that the presently claimed sequence is a "disease-associated gene" or "has gene regulating activity" is **not** the standard for patentability under 35 U.S.C. § 101 (*In re Brana, supra*). Thus, this argument also does not support the Examiner's allegation that the presently claimed sequence lacks a patentable utility.

Therefore, Appellants pointed out in the Response to the First Action and the Response to the Final Action that given the well established biological and medical relevance of platelet derived growth factor proteins, those of skill in the art would readily appreciate the importance of tracking the expression of the genes encoding the described proteins, as described at least at page 5, lines 4-7, in priority document 60/162,547, which was incorporated in its entirety by reference into the present specification as originally filed. In particular, the specification describes how the described sequences can be represented using a gene chip format to provide a high throughput analysis of the level of gene expression. Such "DNA chips" clearly have utility, as evidenced by hundreds of issued U.S. Patents, as exemplified by U.S. Patent Nos. 5,445,934, 5,556,752, 5,744,305, 5,837,832, 6,156,501 and 6,261,776 (**Exhibits D-I**; copies of issued U.S. Patents not provided pursuant to current United States Patent and Trademark Office policy). Given the widespread utility of such "gene chip" methods using *public domain* gene sequence information, there can be little doubt that the use of the presently described *novel* sequences would have great utility in such DNA chip applications. As the present sequences are specific markers of the human genome (see below), and such specific markers are targets for the discovery of drugs that are associated with human disease,

those of skill in the art would instantly recognize that the present nucleotide sequences would be ideal, novel candidates for assessing gene expression using such DNA chips. Clearly, compositions that enhance the utility of such DNA chips, such as the presently claimed nucleotide sequences, must in themselves be useful. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Further evidence of the “real world” substantial utility of the present invention is further provided by the fact that there is an entire industry established based on the use of gene sequences or fragments thereof in a gene chip format. Perhaps the most notable gene chip company is Affymetrix. However, there are many companies that have, at one time or another, concentrated on the use of gene sequences or fragments, in gene chip and non-gene chip formats, for example: Gene Logic, ABI-Perkin-Elmer, HySeq and Incyte. In addition, one such company (Rosetta Inpharmatics) was viewed to have such “real world” value that it was acquired by large a pharmaceutical company (Merck) for significant sums of money (net equity value of the transaction was \$620 million). The “real world” substantial industrial utility of gene sequences or fragments would, therefore, appear to be widespread and well established. Clearly, there can be no doubt that the skilled artisan would know how to use the presently claimed sequences (see Section VIII(B), below), strongly arguing that the claimed sequences have utility. Persons of skill in the art, as well as venture capitalists and investors, readily recognize the utility, both scientific and commercial, of genomic data in general, and specifically human genomic data. Billions of dollars have been invested in the human genome project, resulting in useful genomic data (see, *e.g.*, Venter *et al.*, *Science* **291**:1304, 2001). The results have been a stunning success as the utility of human genomic data has been widely recognized as a great gift to humanity (see, *e.g.*, Jasny and Kennedy, *Science* **291**:1153, 2001). Clearly, the usefulness of human genomic data, such as the presently claimed nucleic acid molecules, is substantial and credible (worthy of billions of dollars and the creation of numerous companies focused on such information) and well-established (the utility of human genomic information has been clearly understood for many years). Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

The Advisory Action questions this assertion of utility, stating that “(c)ontrary to Applicants’ assertion, the claims in the cited patents are drawn to the apparatus, the instant claims are drawn to a (*sic*) isolated nucleic acid” (the Advisory Action at page 2). Appellants state for the record that

it has never been asserted by Appellants that the present claims are “drawn to” gene chips. Rather, it is, and always has been, Appellants position that the presently claimed sequences have utility in assessing gene expression patterns using such gene chips as those described in the issued U.S. Patents described above. Thus, this argument in no way supports the alleged lack of utility. Additionally, Appellants reiterate that the requirements of a specific utility should not be confused with a requirement for a unique utility. Simply because other polynucleotide sequences can be used to track gene expression on a gene chip does not mean that the use of the presently claimed nucleic acid sequence in gene chip applications is not a specific utility (*Carl Zeiss, supra*).

Although Appellants need only make one credible assertion of utility to meet the requirements of 35 U.S.C. § 101 (*Raytheon v. Roper*, 220 USPQ 592 (Fed. Cir. 1983); *In re Gottlieb*, 140 USPQ 665 (CCPA 1964); *In re Malachowski*, 189 USPQ 432 (CCPA 1976); *Hoffman v. Klaus*, 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988)), Appellants noted in the Response to the First Action and the Response to the Final Action, as a further example of the utility of the presently claimed polynucleotide, as described in the specification at least at page 10, lines 34-35, the present nucleotide sequences have a specific utility in “determining the genomic structure”, for example in the identification of coding sequence and mapping the gene to a particular chromosome. This is evidenced by the fact that SEQ ID NO:6 can be used to map the 5 coding exons on chromosome 4 (present within two overlapping chromosome 4 clones; GenBank Accession Numbers AC093325 and AC092608; copies of the alignments and the first page from the GenBank reports that were provided with the Response to the First Action and the Response to the Final Action are provided in **Exhibit J**). Appellants respectfully remind the Board that only a minor percentage (2-4%) of the genome actually encodes exons, which in-turn encode amino acid sequences. The presently claimed polynucleotide sequence provides biologically validated empirical data (*e.g.*, showing which sequences are transcribed, spliced, and polyadenylated) that *specifically* define that portion of the corresponding genomic locus that actually encodes exon sequence. Equally significant is that the claimed polynucleotide sequence defines how the encoded exons are actually spliced together to produce an active transcript (*i.e.*, the described sequences are useful for functionally defining exon splice-junctions). Such biologically validated splice junctions are superior to splice junctions that may have been predicted from genomic sequence alone, and, as detailed in the specification, at least

from page 10, line 36 to page 11, line 3, that “sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (*e.g.*, splice acceptor and/or donor sites), *etc.*, that can be used in diagnostics and pharmacogenomics”. Appellants respectfully submit that the practical scientific value of biologically validated, expressed, spliced, and polyadenylated mRNA sequences is readily apparent to those skilled in the relevant biological and biochemical arts.

Clearly, the present polynucleotide provides exquisite specificity in localizing the specific region of human chromosome 4 that contains the gene encoding the given polynucleotide, a utility not shared by virtually any other nucleic acid sequences. In fact, it is this specificity that makes this particular sequence so useful. Early gene mapping techniques relied on methods such as Giemsa staining to identify regions of chromosomes. However, such techniques produced genetic maps with a resolution of only 5 to 10 megabases, far too low to be of much help in identifying specific genes involved in disease. The skilled artisan readily appreciates the significant benefit afforded by markers that map a specific locus of the human genome, such as the present nucleic acid sequence. For further evidence in support of the Appellants’ position, the Board is requested to review, for example, section 3 of Venter *et al.* (*supra*, at pp. 1317-1321, including Fig. 11 at pp.1324-1325), which demonstrates the significance of expressed sequence information in the structural analysis of genomic data. The presently claimed polynucleotide sequence defines a biologically validated sequence that provides a unique and specific resource for mapping the genome essentially as described in the Venter *et al.* article. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

The Examiner also questioned these asserted utilities, stating that “any chromosome region 4 gene can be used to map that particular area of the chromosome” (the Final Action at page 6), and reiterating this position in the Advisory Action: “there are other sequence (*sic*) which (*sic*) would map to the same region” (the Advisory Action at page 2). First, Appellants respectfully point out that only those small percentage of nucleotide sequences that are located in this region of chromosome 4 can be used in such a manner, and not just “any polynucleotide”. Second The Examiner once again seems to be confusing the requirements of a specific utility with a unique utility. The fact that a small number of other nucleotide sequences could be used to map the protein

coding regions in this specific region of chromosome 4 does not mean that the use of Appellants' sequence to map the protein coding regions of chromosome 4 is not a specific utility (*Carl Zeiss, supra*). The holding in *Carl Zeiss*, and particularly the quote provided above, clearly states that an invention does not need to be the only way to accomplish a certain result. Thus, the question of whether or not other nucleic acid sequences can be used to assess gene expression using DNA chips is completely irrelevant to the present utility inquiry. The only relevant question in regard to meeting the standards of 35 U.S.C. § 101 is whether every nucleic acid can be so used - and the clear answer to this question is an emphatic no. Importantly, the holding in *Carl Zeiss* is mandatory legal authority that essentially controls the outcome of the present case. This case, and particularly the cited quote, directly rebuts the Examiner's argument. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Furthermore, regarding the utility requirements under 35 U.S.C. § 101, the Federal Circuit has clearly stated "(t)he threshold of utility is not high: An invention is 'useful' under section 101 if it is capable of providing some identifiable benefit." *Juicy Whip Inc. v. Orange Bang Inc.*, 185 F.3d 1364, 51 USPQ2d 1700 (Fed. Cir. 1999) (citing *Brenner v. Manson*, 383 U.S. 519, 534 (1966)). Additionally, the Federal Circuit has stated that "(t)o violate § 101 the claimed device must be totally incapable of achieving a useful result." *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571, 24 USPQ2d 1401 (Fed. Cir. 1992), emphasis added. *Cross v. Iizuka* (753 F.2d 1040, 224 USPQ 739 (Fed. Cir. 1985); "*Cross*") states "any utility of the claimed compounds is sufficient to satisfy 35 U.S.C. § 101". *Cross* at 748, emphasis added. Indeed, the Federal Circuit recently emphatically confirmed that "anything under the sun that is made by man" is patentable (*State Street Bank & Trust Co. v. Signature Financial Group Inc.*, 149 F.3d 1368, 47 USPQ2d 1596, 1600 (Fed. Cir. 1998), citing the U.S. Supreme Court's decision in *Diamond vs. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (U.S., 1980)). Thus, based on the relevant case law, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Finally, While Appellants are well aware of the new Utility Guidelines set forth by the USPTO, Appellants respectfully point out that the current rules and regulations regarding the examination of patent applications is and always has been the patent laws as set forth in 35 U.S.C. and the patent rules as set forth in 37 C.F.R., not the Manual of Patent Examination Procedure or

particular guidelines for patent examination set forth by the USPTO. Furthermore, it is the job of the judiciary, not the USPTO, to interpret these laws and rules. Appellants are unaware of any significant recent changes in either 35 U.S.C. § 101, or in the interpretation of 35 U.S.C. § 101 by the Supreme Court or the Federal Circuit that is in keeping with the new Utility Guidelines set forth by the USPTO. This is underscored by numerous patents that have been issued over the years that claim nucleic acid fragments that do not comply with the new Utility Guidelines. As examples of such issued U.S. Patents, the Board is invited to review U.S. Patent Nos. 5,817,479, 5,654,173, and 5,552,281 (**Exhibits K-M**; each of which claims short polynucleotides; copies of issued U.S. Patents not provided pursuant to current United States Patent and Trademark Office policy), and recently issued U.S. Patent No. 6,340,583 (**Exhibit N**; which includes no working examples; copy of issued U.S. Patent not provided pursuant to current United States Patent and Trademark Office policy), none of which contain examples of the “real-world” utilities that the Examiner seems to be requiring. As issued U.S. Patents are presumed to meet all of the requirements for patentability, including 35 U.S.C. §§ 101 and 112, first paragraph (see Section VIII(B), below), Appellants submit that the present polynucleotides must also meet the requirements of 35 U.S.C. § 101. While Appellants understand that each application is examined on its own merits, Appellants are unaware of any changes to 35 U.S.C. § 101, or in the interpretation of 35 U.S.C. § 101 by the Supreme Court or the Federal Circuit, since the issuance of these patents that render the subject matter claimed in these patents, which is similar to the subject matter in question in the present application, as suddenly non-statutory or failing to meet the requirements of 35 U.S.C. § 101. Thus, holding Appellants to a different standard of utility would be arbitrary and capricious, and, like other clear violations of due process, cannot stand.

For each of the foregoing reasons, Appellants submit that the rejection of claims 4-11 under 35 U.S.C. § 101 must be overruled.

**B. Are Claims 4-11 Unusable Due to a Lack of Patentable Utility?**

The Final Action next rejects claims 4-11 under 35 U.S.C. § 112, first paragraph, since allegedly one skilled in the art would not know how to use the invention, as the invention allegedly is not supported by either a clear asserted utility or a well-established utility.

The arguments detailed above in Section VIII(A) concerning the utility of the presently claimed sequences are incorporated herein by reference. As the Federal Circuit and its predecessor have determined that the utility requirement of Section 101 and the how to use requirement of Section 112, first paragraph, have the same basis, specifically the disclosure of a credible utility (*In re Brana, supra*; *In re Jolles*, 628 F.2d 1322, 1326 n.11, 206 USPQ 885, 889 n.11 (CCPA 1980); *In re Fouche*, 439 F.2d 1237, 1243, 169 USPQ 429, 434 (CCPA 1971)), Appellants submit that as claims 4-11 have been shown to have “a specific, substantial, and credible utility”, as detailed in Section VIII(A) above, the present rejection of claims 4-11 under 35 U.S.C. § 112, first paragraph, cannot stand.

Appellants therefore submit that the rejection of claims 4-11 under 35 U.S.C. § 112, first paragraph, must be overruled.

#### **C. Are Claims 4, 7 and 8 Enabled?**

The Final Action next rejected claims 4, 7 and 8 under 35 U.S.C. § 112, first paragraph, as allegedly not described in the specification in such a way as to enable one skilled in the art to make and/or use the invention.

Appellants have repeatedly pointed out that there is absolutely no requirement that all species of an invention must have all of the exact same properties. While the Examiner apparently agrees, stating “(t)here is no requirement that all species of an invention have the exact same properties” (the Final Action at page 8), **every single argument** put forth by the Examiner to support the present rejection hinges on the fact that fragments of SEQ ID NO:6 do not have the same functional characteristics as the full length sequence of SEQ ID NO:6, or the full length amino acid sequence of SEQ ID NO:7. In the First Action, the Examiner stated that “the specification is not enabled for fragments of polynucleotides” because “the changes which can be made in the structure and still maintain sufficient activity is unpredictable” (the First Action at page 6). The Examiner appears to be requiring the polynucleotide fragments to have the same “structure” and “activity” as the full length protein encoded by SEQ ID NO:6. In the Final Action, the Examiner states that “there is no assurance that when the DNA is expressed, the protein would have the desirable properties of the invention” (the Final Action bridging pages 8 and 9). The Examiner appears to believe that the only

“desirable property” that a polynucleotide fragment of the present invention could have is the specific biological properties of the full length protein encoded by SEQ ID NO:6. In the Advisory Action, the Examiner continues this misguided analysis of the enablement requirement: “(a) fragment containing at least 24 contiguous bases could not be used in recombinant expression because a functional protein would not be made” (the Advisory Action at page 2). **None** of these arguments are in the least bit consistent with the Examiner’s repeated assertions that “(t)he Examiner stated specifically that there is no requirement that all species of an invention have the exact same properties” (the Advisory Action at page 2), and, most importantly, in **no way whatsoever** support the allegation that claims 4, 7 and 8 are not enabled.

The Examiner stated that “the rejected claims encompass fragments of NHP which (sic) do not have a property” (Action at page 8), and reiterates this position in the Advisory Action. However, as pointed out by Appellants in the Response to the Final Action, this allegation is quite simply **completely and totally false**. **At the very least**, as there are no art rejections against polynucleotide fragments comprising at least 24 contiguous bases of nucleotide sequence from SEQ ID NO:6, these fragments have the property of being unique identifiers of SEQ ID NO:6. Appellants also pointed out that significant commercial exploitation of nucleic acid sequences requires no more information than the **nucleic acid sequence itself**. Applications ranging from gene expression analysis or profiling (utilizing, for example, arrays of short, overlapping or non-overlapping, oligonucleotides and DNA chips, as described in Section VIII(A), above) to chromosomal mapping (utilizing, for example, short oligonucleotide probes or full length DNA sequences, as described in Section VIII(A), above) are practiced utilizing nucleic acid sequences and techniques that are well-known to those of skill in the art. The widespread commercial exploitation of nucleic acid sequence information points to the level of skill in the art, and the enablement provided by disclosures such as the present specification, which include specific nucleic acid sequences and guidance regarding the various uses of such sequences. Appellants pointed out in both the Response to the First Action and the Response to the Final Action that it is well established that the enablement requirement is met if **any** use of the invention (or in this case, certain species of the invention) is provided (*In re Nelson*, 126 USPQ 242 (CCPA 1960); *Cross v. Iizuka, supra*). “The enablement requirement is met if the description enables any mode of making and using the invention.” *Johns Hopkins Univ. v.*



*CellPro, Inc.*, 47 USPQ2d 1705, 1719 (Fed. Cir. 1998), citing *Engel Indus., Inc. v. Lockformer Co.*, 20 USPQ2d 1300, 1304 (Fed. Cir. 1991). The skilled artisan can clearly make and use the claimed polynucleotides, which is **all that is required** to meet the enablement requirement under 35 U.S.C. § 112, first paragraph. As this is the proper standard, and **not** that the polynucleotide fragments “maintain sufficient activity” or encode “a functional protein”, claims 4, 7 and 8 clearly meet the requirements of 35 U.S.C. § 112, first paragraph.

The Examiner then states that “(i)n the absence of specific hybridization language, the polynucleotide fragment may correspond to any region that is highly conserved in a gene family” and that “(i)t allows imperfect matches and carry (*sic*) the risk of obtaining false signals from unrelated DNA sequences”, and therefore “(t)he specification is not enabled for unrelated sequences which (*sic*) may cross hybridize with the instant invention” (the Advisory Action at page 2). Appellants respectfully point out that claims 4, 7 and 8 do **not** concern hybridization **at all**. Claim 4 (and therefore dependent claims 7 and 8) requires “at least 24 contiguous bases of nucleotide sequence first disclosed in the NHP gene described in SEQ ID NO:6”, and thus does not allow “imperfect matches”. Furthermore, as there are **no** art rejections against polynucleotide fragments comprising at least 24 contiguous bases of nucleotide sequence from SEQ ID NO:6, the Examiner’s conclusion that “the polynucleotide fragment may correspond to any region that is highly conserved in a gene family” is completely and totally unfounded. Thus, these arguments in **no way** support the Examiner’s position that claims 4, 7 and 8 are not enabled.

The Examiner questions the teaching and guidance in the specification for certain aspects of the present invention. However, as discussed above, this requirement is completely misplaced. There is sufficient knowledge and technical skill in the art for a skilled artisan to be able to make and use the claimed DNA species in a number of different aspects of the invention entirely without further details in a patent specification. For example, it is not unreasonable to expect a Ph.D. level molecular biologist to be able to use the disclosed sequence to design oligonucleotide probes and primers and use them in, for example, PCR based screening and detection methods to obtain the described sequences and/or determine tissue expression patterns. Nevertheless, the present specification provides highly detailed descriptions of techniques that can be used to accomplish many different aspects of the claimed invention, including recombinant expression, site-specific

mutagenesis, *in situ* hybridization, and large scale nucleic acid screening techniques, and properly incorporates by reference a montage of standard texts into the specification, such as Sambrook *et al.* (*Molecular Cloning, A Laboratory Manual*) and Ausubel *et al.* (*Current Protocols in Molecular Biology*) to provide even further guidance to the skilled artisan. Incorporation of material into the specification by reference is proper. *Ex parte Schwarze*, 151 USPQ 426 (PTO Bd. App. 1966). The § 112, first paragraph rejection is thus *prima facie* improper:

As a matter of patent office practice, then, a specification disclosure which contains a teaching of the manner and process of making and using the invention in terms which correspond in scope to those used in describing and defining the subject matter sought to be patented must be taken as in compliance with the enabling requirement of the first paragraph of § 112 unless there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support.

*In re Marzocchi*, 169 USPQ 367, 369 (CCPA 1971), emphasis as in original. In any event, an alleged lack of express teaching is insufficient to support a first paragraph rejection where one of skill in the art would know how to perform techniques required to perform at least one aspect of the invention. As a matter of law, it is well settled that a patent need not disclose what is well known in the art. *In re Wands, supra*. In fact, it is preferable that what is well known in the art be omitted from the disclosure. *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 231 USPQ 81 (Fed. Cir. 1986). As standard molecular biological techniques are routine in the art, such protocols do not need to be described in detail in the specification.

The Examiner has repeatedly stated that the specification provides insufficient guidance regarding the biological function or activity of certain of the claimed compositions. However, such an enablement standard conflicts with established patent law. As discussed *In re Brana (supra; "Brana")*, the Federal Circuit admonished the P.T.O. for confusing "the requirements under the law for obtaining a patent with the requirements for obtaining government approval to market a particular drug for human consumption". *Brana* at 1442. The Examiner cited *In re Wands (supra; "Wands")* for the proposition that the present invention could not be practiced without "undue experimentation". However, it is important to remember that in assessing the question of whether undue experimentation would be required in order to practice the claimed invention, the key term is "undue", not "experimentation". *In re Angstadt and Griffin, supra*. In *Wands*, the P.T.O. took the position that the applicant failed to demonstrate that the disclosed biological processes of

immunization and antibody selection could reproducibly result in a useful biological product (antibodies from hybridomas) within the scope of the claims. In its decision overturning the P.T.O.'s rejection, the Federal Circuit found that Wands' demonstration of success in four out of nine cell lines screened was sufficient to support a conclusion of enablement. The court emphasized that the need for some experimentation requiring, *e.g.*, production of the biological material followed by routine screening, was not a basis for a finding of non-enablement, stating:

Disclosure in application for the immunoassay method patent does not fail to meet enablement requirement of 35 USC 112 by requiring 'undue experimentation,' even though production of monoclonal antibodies necessary to practice invention first requires production and screening of numerous antibody producing cells or 'hybridomas,' since practitioners of art are prepared to screen negative hybridomas in order to find those that produce desired antibodies, since in monoclonal antibody art one 'experiment' is not simply screening of one hybridoma but rather is entire attempt to make desired antibody, and since record indicates that amount of effort needed to obtain desired antibodies is not excessive, in view of Applicants' success in each attempt to produce antibody that satisfied all claim limitations.

*Wands* at 1400. Thus, the need for some experimentation does not render the claimed invention unpatentable under 35 U.S.C. § 112, first paragraph. Indeed, a considerable amount of experimentation may be permissible if such experimentation is routinely practiced in the art. *In re Angstadt and Griffin, supra*; *Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., supra*.

Furthermore, a specification "need describe the invention only in such detail as to enable a person skilled in the most relevant art to make and use it." *In re Naquin*, 158 USPQ 317, 319 (CCPA 1968); emphasis added. The present claims are thus enabled as they are supported by a specification that provides sufficient description to enable the skilled person to make and use the invention as claimed. Appellants stress that enablement must be analyzed, not in a vacuum, but "as it would be interpreted by one possessing the ordinary level of skill in the pertinent art." *In re Moore*, 169 USPQ 236, 238 (CCPA 1971). As described in detail above, the specification details numerous applications in which claimed nucleotide sequences can be used, for example, to track gene expression using gene chips. Further, since public domain nucleotide sequences that have not been associated with any particular biological function, let alone validated as coding sequences, are used every day in gene chip applications, it defies logic that undue experimentation would be required to use the presently described nucleotide sequences, which have been biologically validated as coding

sequences, in the very same gene chip applications. Therefore, claims 4, 7 and 8 clearly meet the requirements of 35 U.S.C. § 112, first paragraph.

Appellants therefore submit that the rejection of claims 4, 7 and 8 under 35 U.S.C. § 112, first paragraph, must be overruled.

**D. Does Claim 4 Lack Sufficient Written Description?**

The Final Action next rejected claim 4 under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

35 U.S.C. § 112, first paragraph, requires that the specification contain a written description of the invention. The Federal Circuit in *Vas-Cath Inc. v. Mahurkar* (19 USPQ2d 1111 (Fed. Cir. 1991); “*Vas-Cath*”) held that an “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention.” *Vas-Cath*, at 1117, emphasis in original. However, it is important to note that the above finding uses the terms reasonable clarity to those skilled in the art. Further, the Federal Circuit in *In re Gosteli* (10 USPQ2d 1614 (Fed. Cir. 1989); “*Gosteli*”) held:

Although [the applicant] does not have to describe exactly the subject matter claimed, . . . the description must clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.

*Gosteli* at 1618, emphasis added. Additionally, *Utter v. Hiraga* (6 USPQ2d 1709 (Fed. Cir. 1988); “*Utter*”), held “(a) specification may, within the meaning of 35 U.S.C. § 112 ¶1, contain a written description of a broadly claimed invention without describing all species that claim encompasses” (*Utter*, at 1714). Therefore, all Appellants must do to comply with 35 U.S.C. § 112, first paragraph, is to convey the invention with reasonable clarity to the skilled artisan.

The Examiner stated that claim 4 fails to meet the written description requirement because the specification “discloses only a structural feature” (the Final Action at page 10), and reiterates this position in the Advisory Action. Appellants have repeatedly pointed out that this is all that is required for claim 4 to meet the written description requirement of 35 U.S.C. § 112, first paragraph.

The Federal Circuit has held that an adequate description of a chemical genus “requires a precise definition, such as by structure, formula, chemical name or physical properties” sufficient to distinguish the genus from other materials. *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993; “*Fiers*”). *Fiers* goes on to hold that the “application satisfies the written description requirement since it sets forth the . . . nucleotide sequence” (*Fiers* at 1607). In other words, provision of a structure and formula - the nucleotide sequence - renders the application in compliance with 35 U.S.C. § 112, first paragraph.

More recently, the standard for complying with the written description requirement in claims involving chemical materials has been explicitly set forth by the Federal Circuit:

In claims involving chemical materials, generic formulae usually indicate with specificity what the generic claims encompass. One skilled in the art can distinguish such a formula from others and can identify many of the species that the claims encompass. Accordingly, such a formula is normally an adequate description of the claimed genus. *Regents of Univ. of California v. Eli Lilly and Co.*, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997).

Thus, a claim describing a genus of nucleic acids by structure, formula, chemical name or physical properties sufficient to allow one of ordinary skill in the art to distinguish the genus from other materials meets the written description requirement of 35 U.S.C. § 112, first paragraph. As further elaborated by the Federal Circuit in *Regents of Univ. of California v. Eli Lilly and Co.*:

In claims to genetic material ... a generic statement such as ‘vertebrate insulin cDNA’ or ‘mammalian insulin cDNA’, without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art cannot, as one can do with a fully described genus, visualize or recognize the identity of members of the genus. (Emphasis added)

Thus, as opposed to the situation set forth in *Regents of Univ. of California v. Eli Lilly and Co.* and *Fiers*, the nucleic acid sequences of the present invention are not distinguished on the basis of function, or a method of isolation, but in fact are distinguished by structural features - a chemical formula, i.e., the *sequence itself*.

Using the nucleic acid sequences of the present invention (as set forth in the Sequence Listing), the skilled artisan would readily be able to **distinguish** the claimed nucleic acids from other

materials on the basis of the specific **structural** description provided. Polynucleotides comprising at least 24 contiguous bases from SEQ ID NO:6 are within the genus of the instant claims, while those that lack this **structural** feature lie outside the genus. The claimed genus of polynucleotides is clearly defined in structural terms, which is **all that is required** of claim 4 in order to meet the written description requirement of 35 U.S.C. § 112, first paragraph.

The Examiner states that “(t)hese 24 contiguous bases can come from a completely different nucleotide sequence, not just SEQ ID NO:6” (the Advisory Action at page 2). Appellants reiterate that, as there are **no** art rejections against polynucleotide fragments comprising at least 24 contiguous bases of nucleotide sequence from SEQ ID NO:6, this **unsubstantiated** conclusion by the Examiner in **no way** satisfies the Examiner’s burden of establishing a prima facie case that claim 4 lacks sufficient written description support, let alone serves to overcome the controlling legal precedent cited by Appellants. As the claimed genus of polynucleotides is clearly defined in **structural** terms that allows the skilled artisan to **distinguish** the claimed nucleic acids from other materials, claim 4 clearly meets the written description requirement of 35 U.S.C. § 112, first paragraph.

For each of the foregoing reasons, Appellants submit that the rejection of claim 4 under 35 U.S.C. § 112, first paragraph, must be overruled.

## **IX. APPENDIX**

The claims involved in this appeal are as follows:

4. (Original) An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in the NHP gene described in SEQ ID NO:6.

5. (Previously Presented) An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO:7; and
- (b) hybridizes to the nucleotide sequence of SEQ ID NO:6 or the complement thereof under highly stringent conditions of 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS) and 1 mM EDTA at 65°C and washing in 0.1x SSC/0.1%SDS at 68°C.

6. (Original) An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:7.

7. (Previously Presented) A recombinant expression vector comprising the isolated nucleic acid molecule of claim 4.

8. (Previously Presented) A host cell comprising the recombinant expression vector of claim 7.

9. (Previously Presented) The isolated nucleic acid molecule of claim 4, comprising the nucleic acid sequence of SEQ ID NO:6.

10. (Previously Presented) The recombinant expression vector of claim 7, wherein said nucleic acid molecule encodes the amino acid sequence shown in SEQ ID NO:7.

11. (Previously Presented) The recombinant expression vector of claim 10, wherein said

nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:6.




**X. CONCLUSION**

Appellants respectfully submit that, in light of the foregoing arguments, the Final Action's conclusion that claims 4-11 lack a patentable utility and are unusable by the skilled artisan due to a lack of patentable utility, that claims 4, 7 and 8 are not enabled, and that claim 4 lacks sufficient written description, is unwarranted. It is therefore requested that the Board overturn the Final Action's rejections.

Respectfully submitted,

February 19, 2004

Date




David W. Hibler  
Agent For Appellants

Reg. No. 41,071

LEXICON GENETICS INCORPORATED  
8800 Technology Forest Place  
The Woodlands, TX 77381  
(281) 863-3399

Customer # 24231



## TABLE OF AUTHORITIES

### CASES

<i>Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.</i> , 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991) .....	9, 24
<i>Brooktree Corp. v. Advanced Micro Devices, Inc.</i> , 977 F.2d 1555, 1571, 24 USPQ2d 1401 (Fed. Cir. 1992) .....	18
<i>Carl Zeiss Stiftung v. Renishaw PLC</i> , 20 USPQ2d 1101 (Fed. Cir. 1991) (citing <i>Envirotech Corp. v. Al George, Inc.</i> , 221 USPQ 473, 480 (Fed. Cir. 1984)) .....	7, 15, 17
<i>Cross v. Iizuka</i> , 753 F.2d 1040, 224 USPQ 739 (Fed. Cir. 1985) .....	18, 21
<i>Diamond vs. Chakrabarty</i> , 447 U.S. 303, 206 USPQ 193 (U.S., 1980) .....	18
<i>Ex parte Schwarze</i> , 151 USPQ 426 (PTO Bd. App. 1966) .....	22
<i>Fiers v. Revel</i> , 984 F.2d 1164, 25 USPQ2d 1601 (Fed. Cir. 1993) .....	25, 26
<i>Hoffman v. Klaus</i> , 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988) .....	15
<i>Hybritech, Inc. v. Monoclonal Antibodies</i> , 802 F.2d 1367, 1385, 231 USPQ 81, 94-95 (Fed. Cir. 1986) .....	23
<i>In re Angstadt and Griffin</i> , 537 F.2d 498, 190 USPQ 214 (CCPA 1976) .....	9, 23, 24
<i>In re Brana</i> , 51 F.3d 1560, 34 USPQ2d 1436 (Fed. Cir. 1995) .....	8, 9, 13, 19, 23



<i>In re Fouche</i> , 439 F.2d 1237, 1243, 169 USPQ 429, 434 (CCPA 1971) .....	19
<i>In re Gosteli</i> , 872 F.2d 1008, 10 USPQ2d 1614 (Fed. Cir. 1989) .....	25
<i>In re Gottlieb</i> , 328 F.2d 1016, 140 USPQ 665 (CCPA 1964) .....	15
<i>In re Jolles</i> , 628 F.2d 1322, 1326 n.11, 206 USPQ 885, 889 n.11 (CCPA 1980) .....	19
<i>In re Langer</i> , 503 F.2d 1380, 183 USPQ 288 (CCPA 1974) .....	9
<i>In re Malachowski</i> , 530 F.2d 1402, 189 USPQ 432 (CCPA 1976) .....	15
<i>In re Marzocchi</i> , 439 F.2d 220, 224, 169 USPQ 367, 370 (CCPA, 1971) .....	9, 22
<i>In re Moore</i> , 439 F.2d 1232, 169 USPQ 236 (CCPA 1971) .....	24
<i>In re Naquin</i> , 158 USPQ 317, 319 (CCPA 1968) .....	24
<i>In re Nelson</i> , 280 F.2d 172, 126 USPQ 242 (CCPA 1960) .....	21
<i>In re Wands</i> , 858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988) .....	6, 9, 23, 24
<i>Johns Hopkins Univ. v. CellPro, Inc.</i> , 152 F.3d 1342, 47 USPQ2d 1705, 1719 (Fed. Cir. 1998) (citing <i>Engel Indus., Inc. v. Lockformer Co.</i> , 946 F.2d 1528, 20 USPQ2d 1300, 1304 (Fed. Cir. 1991)) .....	21
<i>Juicy Whip Inc. v. Orange Bang Inc.</i> , 185 F.3d 1364, 51 USPQ2d 1700 (Fed. Cir. 1999) (citing <i>Brenner v. Manson</i> , 383 U.S. 519, 534 (1966)) .....	17

<i>Raytheon Co. v. Roper Corp.</i> , 724 F.2d 951, 220 USPQ 592 (Fed. Cir. 1983) .....	15
<i>Regents of Univ. of California v. Eli Lilly and Co.</i> , 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997) .....	25, 26
<i>State Street Bank &amp; Trust Co. v. Signature Financial Group Inc.</i> , 149 F.3d 1368, 47 USPQ2d 1596, 1600 (Fed. Cir. 1998) .....	18
<i>Utter v. Hiraga</i> , 845 F.2d 993, 6 USPQ2d 1709 (Fed. Cir. 1988) .....	25
<i>Vas-Cath Inc. v. Mahurkar</i> , 935 F.2d 1555, 19 USPQ2d 1111 (Fed. Cir. 1991) .....	24, 25

## **STATUTES**

35 U.S.C. § 101 ..... 2-4, 7-10, 12-15, 17-19

35 U.S.C. § 112 ..... 2-4, 8, 18, 19, 21-27



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

for

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show: 20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Nat Cell Biol 2000 May;2(5):302-9

Related Articles, Link

nature  
cell biology

**PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.**

Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U.

Ludwig Institute for Cancer Research, Stockholm, Sweden.

Platelet-derived growth factors (PDGFs) are important in many types of mesenchymal cell. Here we identify a new PDGF, PDGF-C, which binds to and activates the PDGF alpha-receptor. PDGF-C is activated by proteolysis and induces proliferation of fibroblasts when overexpressed in transgenic mice. In situ hybridization analysis in the murine embryonic kidney shows preferential expression of PDGF-C messenger RNA in the metanephric mesenchyme during epithelial conversion. Analysis of kidneys lacking the PDGF alpha-receptor shows selective loss of mesenchymal cells adjacent to sites of expression of PDGF-C mRNA; this is not found in kidneys from animals lacking PDGF-A or both PDGF-A and PDGF-B, indicating that PDGF-C may have a unique function.

PMID: 10806482 [PubMed - indexed for MEDLINE]

Display

Abstract

Show: 20

Sort

Send to

Text


Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

Mar 3 2003 10:01:4



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Bc

Search  for

Limits Preview/Index History Clipboard Details

[About Entrez](#)

Show:  Sort:  Send to:

Text Version

☐ 1: J Biol Chem 2001 Jul 20;276(29):27406-14[Related Articles, Link](#)

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

FREE full text article at  
[www.jbc.org](http://www.jbc.org)

**Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.**

Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, Palmer TE, Hart CE.

ZymoGenetics Inc., Seattle, Washington 98102, USA. gilbertd@zgi.com

We have characterized platelet-derived growth factor (PDGF) C, a novel growth factor belonging to the PDGF family. PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%). A serum-sensitive cleavage site between the two domains allows release of the GFD from the CUB domain. Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers. PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types. Analysis of PDGF-CC in vivo in a diabetic mouse model of delayed wound healing showed that PDGF-CC significantly enhanced repair of a full-thickness skin excision. Together, these studies describe a third member of the PDGF family (PDGF-C) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to PDGF-AB.

PMID: 11297552 [PubMed - indexed for MEDLINE]

Show:  Sort:  Send to:

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

>NM\_016205 ACCESSION:NM\_016205 NID: gi 9994186 ref NM\_016205.1 Homo  
sapiens platelet derived growth factor C (PDGFC), mRNA  
Length = 3007

Score = 486 bits (1237), Expect = e-135  
Identities = 234/234 (100%), Positives = 234/234 (100%)  
Frame = +3


Query: 1 MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 60  
MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS  
Sbjct: 492 MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 671  
Query: 61 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 120  
PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL  
Sbjct: 672 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 851  
Query: 121 GRWCGSGTVPKGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 180  
GRWCGSGTVPKGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA  
Sbjct: 852 GRWCGSGTVPKGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 1031  
Query: 181 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKS 234  
LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKS  
Sbjct: 1032 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKS 1193

>AF260738 ACCESSION:AF260738 NID: gi 14009503 gb AF260738.1 AF260738  
Homo sapiens platelet-derived growth factor C (PDGFC)  
mRNA, complete cds  
Length = 1804

Score = 486 bits (1237), Expect = e-135  
Identities = 234/234 (100%), Positives = 234/234 (100%)  
Frame = +1

Query: 1 MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 60  
MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS  
Sbjct: 163 MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 342  
Query: 61 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 120  
PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL  
Sbjct: 343 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 522  
Query: 121 GRWCGSGTVPKGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 180  
GRWCGSGTVPKGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA  
Sbjct: 523 GRWCGSGTVPKGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 702  
Query: 181 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKS 234  
LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKS  
Sbjct: 703 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKS 864





[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Boo](#)

Search  for

☐ 1: NM\_016205. Homo sapiens plat...[gi:9994186]

[Links](#)

LOCUS PDGFC 3007 bp mRNA linear PRI 17-AUG-2001  
 DEFINITION Homo sapiens platelet derived growth factor C (PDGFC), mRNA.  
 ACCESSION NM\_016205  
 VERSION NM\_016205.1 GI:9994186  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 3007)  
 AUTHORS Li,X., Ponten,A., Aase,K., Karlsson,L., Abramsson,A., Uutela,M.,  
 Backstrom,G., Hellstrom,M., Bostrom,H., Li,H., Soriano,P.,  
 Betsholtz,C., Heldin,C.H., Alitalo,K., Ostman,A. and Eriksson,U.

TITLE PDGF-C is a new protease-activated ligand for the PDGF  
 alpha-receptor.

JOURNAL Nat. Cell Biol. 2 (5), 302-309 (2000)

MEDLINE 20268201

PUBMED 10806482

REFERENCE 2 (bases 1 to 3007)

AUTHORS Hamada,T., Ui-Tei,K. and Miyata,Y.

TITLE A novel gene derived from developing spinal cords, SCDGF, is a  
 unique member of the PDGF/VEGF family

JOURNAL FEBS Lett. 475 (2), 97-102 (2000)

MEDLINE 20317014

PUBMED 10858496

REFERENCE 3 (bases 1 to 3007)

AUTHORS Tsai,Y.J., Lee,R.K., Lin,S.P. and Chen,Y.H.

TITLE Identification of a novel platelet-derived growth factor-like gene,  
 fallotein, in the human reproductive tract

JOURNAL Biochim. Biophys. Acta 1492 (1), 196-202 (2000)

MEDLINE 20461776

PUBMED 11004490

REFERENCE 4 (bases 1 to 3007)

AUTHORS Zwerner,J.P. and May,W.A.

TITLE PDGF-C is an EWS/FLI induced transforming growth factor in Ewing  
 family tumors

JOURNAL Oncogene 20 (5), 626-633 (2001)

MEDLINE 21214457

PUBMED 11313995

REFERENCE 5 (bases 1 to 3007)

AUTHORS Uutela,M., Lauren,J., Bergsten,E., Li,X., Horelli-Kuitunen,N.,  
 Eriksson,U. and Alitalo,K.

TITLE Chromosomal location, exon structure, and vascular expression  
 patterns of the human PDGFC and PDGFC genes

JOURNAL Circulation 103 (18), 2242-2247 (2001)

MEDLINE 21266739

PUBMED 11342471

## NCBI Sequence Viewer

REFERENCE 6 (bases 1 to 3007)

AUTHORS Gilbertson,D.G., Duff,M.E., West,J.W., Kelly,J.D., Sheppard,P.O., Hofstrand,P.D., Gao,Z., Shoemaker,K., Bukowski,T.R., Moore,M., Feldhaus,A.L., Humes,J.M., Palmer,T.E. and Hart,C.E.

TITLE Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor

JOURNAL J. Biol. Chem. 276 (29), 27406-27414 (2001)

MEDLINE 21347863

PUBMED 11297552

COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The reference sequence was derived from [AF091434.1](#).  
Summary: The protein encoded by this gene is a member of the platelet-derived growth factor family. The four members of this family are mitogenic factors for cells of mesenchymal origin and are characterized by a core motif of eight cysteines. This gene product appears to form only homodimers. It differs from the platelet-derived growth factor alpha and beta polypeptides in having an unusual N-terminal domain, the CUB domain.  
COMPLETENESS: full length.

FEATURES

source	Location/Qualifiers 1..3007 /organism="Homo sapiens" /db_xref="taxon:9606" /chromosome="4" /map="4q32"
gene	1..3007 /gene="PDGFC" /note="synonym: SCDGF" /db_xref="LocusID:56034"
variation	113 /gene="PDGFC" /allele="T" /allele="C" /db_xref="dbSNP:3733486"
CDS	492..1529 /gene="PDGFC" /note="spinal cord-derived growth factor; secretory growth factor-like protein; fallotein" /codon_start=1 /product="platelet-derived growth factor C precursor" /protein_id="NP_057289.1" /db_xref="GI:9994187" /db_xref="LocusID:56034" /translation="MSLFGLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDP QHERIITVSTNGSIHSPRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDD ICKYDFVEVEEPSDGTILGRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIHY NIVMPQFTEAVSPSVLPSPALPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRP TWQLLGKAFVFGKRSRVVDLNLLEEVRLYSCTPRNFSVSIREELKRTDTIFWPGCLL VKRCGGNCACCLHNCNECQCVPSKVTKKYHEVLQLRPKTGVRGLHKS LTDVALEHHEE CDCVCRGSTGG"
pro_peptide	492..1526 /gene="PDGFC" /note="spinal cord-derived growth factor; secretory growth factor-like protein; fallotein"
sig_peptide	492..533 /gene="PDGFC"
mat_peptide	534..1526 /gene="PDGFC" /product="platelet-derived growth factor C"
misc_feature	651..980

/gene="PDGFC"  
/note="CUB; Region: Domain first found in C1r, C1s, uEGF,  
and bone morphogenetic protein."  
/db\_xref="CDD:smart00042"  
misc\_feature 651..971  
/gene="PDGFC"  
/note="CUB; Region: CUB domain"  
/db\_xref="CDD:pfam00431"  
misc\_feature 1239..1502  
/gene="PDGFC"  
/note="PDGF; Region: Platelet-derived and vascular  
endothelial growth factors (PDGF, VEGF) family"  
/db\_xref="CDD:smart00141"  
misc\_feature 1239..1502  
/gene="PDGFC"  
/note="PDGF; Region: Platelet-derived growth factor  
(PDGF)"  
/db\_xref="CDD:pfam00341"  
misc\_feature 1239..1241  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1311..1313  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1329..1331  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1347..1349  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1350..1352  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1371..1373  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1494..1496  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
misc\_feature 1500..1502  
/gene="PDGFC"  
/note="conserved cysteine; unclassified site"  
variation complement(1523)  
/allele="T"  
/allele="C"  
/db\_xref="dbSNP:3815861"  
variation complement(1909)  
/allele="T"  
/allele="G"  
/db\_xref="dbSNP:1425487"  
variation complement(2086)  
/allele="T"  
/allele="C"  
/db\_xref="dbSNP:1425486"  
variation complement(2464)  
/allele="T"  
/allele="A"  
/db\_xref="dbSNP:3180908"  
variation 2660  
/gene="PDGFC"

## NCBI Sequence Viewer

/allele="T"  
 /allele="C"  
 /db\_xref="dbSNP:1047569"  
 polyA\_signal 2974..2979  
 /gene="PDGFC"  
 polyA\_site 3007  
 /gene="PDGFC"

BASE COUNT 858 a 613 c 635 g 901 t  
 ORIGIN

```


1  gcccggagag  ccgcatctat  tggcagcttt  gttattgata  agaaactgct  cgccgcccga
61  ttggcttcca  gtctggctgc  gggcaaccct  tgagttttcg  cctctgtcct  gtcccccgaa
121  ctgacaggtg  ctcccagcaa  cttgctgggg  acttctcgcc  gtcccccgc  gtccccaccc
181  cctcattcct  ccctcgccct  cacccccacc  cccaccactt  cgccacagct  caggatttgt
241  ttaaactctg  ggaaactggt  tcaggtccag  gttttgcttt  gatccttttc  aaaaactgga
301  gacacagaag  agggctctag  gaaaaagttt  tggatgggat  tatgtggaaa  ctacctgag
361  attctctgct  gccagagcag  gctcggcgct  tccaccccag  tgcagccttc  ccctggcggt
421  ggtgaaagag  actcgggagt  cgctgcttcc  aaagtgcctg  ccgtgagtga  gctctcacc
481  cagtcagcca  aatgagcctc  ttcgggcttc  tcctgctgac  atctgccctg  gccggccaga
541  gacaggggac  tcagggcgaa  tccaacctga  gtagtaaatt  ccagttttcc  agcaacaagg
601  aacagaacgg  agtacaagat  cctcagcatg  agagaattat  tactgtgtct  actaatggaa
661  gtattcacag  cccaaggttt  cctcatactt  atccaagaaa  tacggtcttg  gtatggagat
721  tagtagcagt  agaggaaaat  gtatggatac  aacttacgtt  tgatgaaaga  tttgggcttg
781  aagaccaga  agatgacata  tgcaagtatg  atttttaga  agttgaggaa  cccagtgtg
841  gaactatatt  agggcgctgg  tgtggttctg  gtactgtacc  aggaaaacag  atttctaaag
901  gaaatcaa  taggataaga  tttgtatctg  atgaatattt  tccttctgaa  ccagggttct
961  gcatccacta  caacattgtc  atgccacaat  tcacagaagc  tgtgagtcct  tcagtgtctac
1021  ccccttcagc  tttgccactg  gacctgctta  ataagtctat  aactgccttt  agtaccttgg
1081  aagaccttat  tcgatatctt  gaaccagaga  gatggcagtt  ggacttagaa  gatctatata
1141  ggccaacttg  gcaacttctt  ggcaaggctt  ttgtttttgg  aagaaaatcc  agagtgggtg
1201  atctgaacct  tctaacagag  gaggtaagat  tatacagctg  cacacctcgt  aacttctcag
1261  ttccataaag  ggaagaacta  aagagaaccg  ataccatttt  ctggccaggt  tgtctcctgg
1321  ttaaactctg  tgggtgggaa  tgtgcctgtt  gtctccacaa  ttgcaatgaa  tgtcaatgtg
1381  tcccaagcaa  agttactaaa  aaataccacg  aggtccttca  gttgagacca  aagaccggtg
1441  tcaggggatt  gcacaaatca  ctcaccgacg  tggccctgga  gcaccatgag  gagtgtgact
1501  gtgtgtgcag  agggagcaca  ggaggatagc  cgcataacca  ccagcagctc  ttgcccagag
1561  ctgtgcagtg  cagtggctga  ttctattaga  gaacgtatgc  gttatctcca  tccttaatct
1621  cagttgtttg  cttcaaggac  ctttcatctt  caggatttac  agtgcattct  gaaagaggag
1681  acatcaaaca  gaattaggag  ttgtgcacaa  gctcttttga  gaggaggcct  aaaggacagg
1741  agaaaaggtc  ttcaatcgtg  gaaagaaaat  taaatgttgt  attaaataga  tcaccagcta
1801  gtttccagag  taccatgtac  gtattccact  agctgggttc  tgtatttcag  ttctttcgat
1861  acggcttagg  gtaatgtcag  tacaggaaaa  aaactgtgca  agtgagcacc  tgattccggt
1921  gccttgctta  actctaaagc  tccatgtcct  gggcctaaaa  tcgtataaaa  tctggatttt
1981  tttttttttt  tttgtctata  ttcacatatg  taaaccagaa  cattctatgt  actacaaacc
2041  tggtttttaa  aaaggaacta  tgttgctatg  aattaaactt  gtgtcgtgct  gataggacag
2101  actggatttt  tcatatttct  tattaaat  tctgccattt  agaagaagag  aactacattc
2161  atgggtttga  agagataaac  ctgaaaagaa  gatggcctt  atcttcaact  tatcgataag
2221  tcagtttatt  tgtttcattg  tgtacatttt  tatattctcc  ttttgacatt  ataactgttg
2281  gctttttctaa  tcttgtttaa  tatattctatt  tttaccaaag  gtatttaata  ttctttttta
2341  tgacaactta  gatcaactat  ttttagcttg  gtaaattttt  ctaaacacaa  ttgttatagc
2401  cagaggaaca  aagatgatat  aaaatattgt  tgctctgaca  aaaatacatg  tatttcattc
2461  tcgtatgggtg  cttagagttag  attaatctgc  attttaaaaa  actgaattgg  aatagaattg
2521  gtaagtgtga  aagacttttt  gaaaataatt  aaattatcat  atcttccatt  cctgttattg
2581  gagatgaaaa  taaaaagcaa  cttatgaaag  tagacattca  gatccagcca  ttgaaaaaga
2641  attccttttt  tggggaaatc  tgagcctagc  tcagaaaaac  ataaagcacc  ttgaaaaaga
2701  cttggcagct  tcctgataaa  gcgtgctgtg  ctgtgcagta  ggaacacatc  ctatttattg
2761  tgatgttgtg  gttttattat  cttaaactct  gtccataaca  cttgtataaa  tacatggata
2821  tttttatgta  cagaagtatg  tctcttaacc  agttcactta  ttgtactctg  gcaattttaa
2881  agaaaatcag  taaaatattt  tgcttgtaaa  atgcttaata  tcgtgcctag  gttatgtggg
2941  gactatttga  atcaaaaatg  tattgaatca  tcaataaaaa  gaatgtggct  attttgggga
3001  gaaaatt
  
```

//

Revised: July 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

Mar 3 2003 10:13:39



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Boo

Search  for

Limits Preview/Index History Clipboard Details

Display  Show:

☐ 1: AF260738. Homo sapiens plat...[gi:14009503]

Links

LOCUS AF260738 1804 bp mRNA linear PRI 17-JUL-2001  
DEFINITION Homo sapiens platelet-derived growth factor C (PDGFC) mRNA,  
complete cds.

ACCESSION AF260738  
VERSION AF260738.1 GI:14009503

KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1804)  
AUTHORS Gilbertson,D.G., Duff,M.E., West,J.W., Kelly,J.D., Sheppard,P.O.,  
Hofstrand,P.D., Gao,Z., Shoemaker,K., Bukowski,T.R., Moore,M.,  
Feldhaus,A.L., Humes,J.M., Palmer,T.E. and Hart,C.E.

TITLE Platelet-derived growth factor C (PDGF-C), a novel growth factor  
that binds to PDGF alpha and beta receptor

JOURNAL J. Biol. Chem. 276 (29), 27406-27414 (2001)  
MEDLINE 21347863  
PUBMED 11297552

REFERENCE 2 (bases 1 to 1804)  
AUTHORS Gao,Z., Hart,C., Piddington,C., Sheppard,P., Shoemaker,K.,  
Gilbertson,D., West,J. and O'Hara,P.J.

TITLE Direct Submission  
JOURNAL Submitted (26-APR-2000) Biomolecular Informatics, ZymoGenetics,  
Inc., 1201 Eastlake Avenue East, Seattle, WA 98102, USA

FEATURES Location/Qualifiers  
source

1..1804  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="4"  
/map="4q28.3"

gene 1..1804  
/gene="PDGFC"

CDS 163..1200  
/gene="PDGFC"  
/note="PDGF-C; ZVEGF3"  
/codon\_start=1  
/product="platelet-derived growth factor C"  
/protein\_id="AAK51637.1"  
/db\_xref="GI:14009504"

/translation="MSLFGLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDP  
QHERIITVSTNGSIHSPRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDD  
ICKYDFVEVEEPSDGTILGRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIH  
NIVMPQFTEAVSPSVLPSPALPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRP  
TWQLLGKAFVFGKRSRVVDLNLTEEVRLYSCTPRNFSVSIREELEKRTDTIFWPGCLL  
VKRCGGNCACCLHNCNECQCVPSKVTKKYHEVLQLRPKTGVRGLHKS LTDVALEHHEE  
CDCVCRGSTGG"

BASE COUNT      531 a      375 c      416 g      482 t  
ORIGIN  
1 ggcacgagga ttatgtggaa actaccctgc gattctctgc tgccagagca ggctcggcgc  
61 ttccacccca gtgcagcctt cccctggcgg tggtgaaaga gactcgggag tcgctgcttc  
121 caaagtggcc gccgtgagtg agctctcacc ccagtcagcc aaatgagcct cttcgggctt  
181 ctctgtctga catctgccct ggccggccag agacagggga ctcaggcgga atccaacctg  
241 agtagtaaat tccagttttc cagcaacaag gaacagaacg gagtacaaga tcctcagcat  
301 gagagaatta ttactgtgtc tactaatgga agtattcaca gcccaagggt tcctcatact  
361 tatccaagaa atacgggtctt ggtatggaga ttagtagcag tagaggaaaa tgtatggata  
421 caacttacgt ttgatgaaag atttgggctt gaagaccag aagatgacat atgcaagtat  
481 gattttttag aagttgagga acccagtgat ggaactatat tagggcgctg gtgtggttct  
541 ggtactgtac caggaaaaca gatttctaaa ggaaatcaaa ttaggataag atttgtatct  
601 gatgaatatt ttcttctga accagggttc tgcattccact acaacattgt catgccacaa  
661 ttcacagaag ctgtgagtc ttcagtgtca ccccttcag ctttgccact ggacctgtct  
721 aataatgcta taactgcctt tagtaccttg gaagacctta ttcgatattc tgaaccagag  
781 agatggcagt tggacttaga agatctatat aggccaactt ggcaacttct tggcaaggct  
841 tttgtttttg gaagaaaatc cagagtgggt gatctgaacc ttctaacaga ggaggtaaga  
901 ttatacagct gcacacctcg taacttctca gtgtccataa gggaagaact aaagagaacc  
961 gataccattt tctggccagg ttgtctcctg gttaaacgct gtggtgggaa ctgtgcctgt  
1021 tgtctccaca attgcaatga atgtcaatgt gtcccaagca aagttactaa aaaataccac  
1081 gaggtccttc agttgagacc aaagaccggt gtcaggggat tgcacaaatc actcaccgac  
1141 gtggccctgg agcaccatga ggagtgtgac tgtgtgtgca gaggggagcac aggaggatag  
1201 ccgcatcacc accagcagct cttgcccaga gctgtgcagt gcagtggctg attctattag  
1261 agaacgtatg cgttatctcc atccttaatc tcagttgttt gcttcaagga cctttcatct  
1321 tcaggattta cagtgcattc tgaaagagga gacatcaaac agaattagga gttgtgcaac  
1381 agctcttttg agaggaggcc taaaggacag gagaaaagggt cttcaatcgt ggaaagaaaa  
1441 ttaaattgtt tattaaatag atcaccagct agtttcagag ttaccatgta cgtattccac  
1501 tagctggggt ctgtatttca gttctttcga tacggcttag ggtaattgtca gtacaggaaa  
1561 aaaactgtgc aagtgagcac ctgattccgt tgccttgctt aactctaaag ctccatgtcc  
1621 tgggcctaaa atcgtataaa atctggattt tttttttttt tttttgctca tattcacata  
1681 tgtaaacag aacattctat gtactacaaa cctggttttt aaaaaggaac tatgttgcta  
1741 tgaattaaac ttgtgtcgtg ctgataggaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
1801 aaaa



//

Revised: July 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

Mar 3 2003 10:13:39

Entrez-PubMed



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Bc

Search  for     
Limits Preview/Index History Clipboard Details

About Entrez

Display  Show:  Sort  Send to

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Browser  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

Privacy Policy

1: Biochim Biophys Acta 2000 Jun 21;1492(1):196-202

[Related Articles](#), [Link](#)

**ELSEVIER SCIENCE  
FULL-TEXT ARTICLE**

## Identification of a novel platelet-derived growth factor-like gene, fallotein, in the human reproductive tract.

Tsai YJ, Lee RK, Lin SP, Chen YH.

Division of Reproduction and Endocrinology, Department of Medical Research, Mackay Memorial Hospital, Tamshui, Taiwan.  
yjtsai@ms1.mmh.org.tw

We isolated the cDNA of a novel platelet-derived growth factor-like gene from human endometrium. The gene was named fallotein; it was 3007 bases in length, and encoded a protein of 345 amino acids. Antiserum against the fallotein protein can recognize a specific protein in the fallopian tube, with a molecular size in accordance with the anticipated size of fallotein. Fallotein mRNA is expressed in two molecular sizes, 3.8 and 2.9 kb, with the former being more abundant. High expression of the gene was found in the prostate, testis, and uterus. A weaker expression signal was found in the spleen, thymus, and small intestine, but expression of fallotein in the colon and peripheral blood leukocytes was negligible.

PMID: 11004490 [PubMed - indexed for MEDLINE]

Display  Show:  Sort  Send to

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)

Mar 3 2003 10:01:4





>AF091434 ACCESSION:AF091434 NID: gi 6002592 gb AF091434.1 AF091434  
Homo sapiens secretory growth factor-like protein  
fallotein mRNA, complete cds  
Length = 3007



Score = 486 bits (1237), Expect = e-135  
Identities = 234/234 (100%), Positives = 234/234 (100%)  
Frame = +3

Query: 1 MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 60  
MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS  
Sbjct: 492 MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 671

Query: 61 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 120  
PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL  
Sbjct: 672 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 851

Query: 121 GRWCGSGTVPKGQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 180  
GRWCGSGTVPKGQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA  
Sbjct: 852 GRWCGSGTVPKGQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 1031

Query: 181 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKR 234  
LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKR  
Sbjct: 1032LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGKRKR 1193



Search  for

Display  Show:

1: AF091434. Homo sapiens secr...[gi:6002592]

LOCUS AF091434 3007 bp mRNA linear PRI 22-JUN-2000  
DEFINITION Homo sapiens secretory growth factor-like protein fallotein mRNA,  
complete cds.

ACCESSION AF091434  
VERSION AF091434.1 GI:6002592

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 3007)

AUTHORS Tsai,Y.J., Lee,R.K., Lin,S.P. and Chen,Y.H.

TITLE Identification of a novel platelet-derived growth factor-like gene,  
fallotein, in the human reproductive tract

JOURNAL Biochim. Biophys. Acta 1492 (1), 196-202 (2000)

MEDLINE 20461776

PUBMED 11004490

REFERENCE 2 (bases 1 to 3007)

AUTHORS Tsai,Y.J., Lee,R.K.K. and Lin,S.P.

TITLE Direct Submission

JOURNAL Submitted (14-SEP-1998) Dept. Medical Research, Mackay Memorial  
Hospital, 45 Min Sheng Road, Tamshui, Taipei County 25115, Taiwan

FEATURES

source

Location/Qualifiers

1..3007

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/tissue\_type="uterus"

CDS

492..1529

/note="found in female reproductive tract"

/codon\_start=1

/evidence=not\_experimental

/product="secretory growth factor-like protein fallotein"

/protein\_id="AAF00049.1"

/db\_xref="GI:6002593"

/translation="MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDP  
QHERIITVSTNGSIHSPRPHPTYPRTVLVWRLVAVEENVWIQLTFDERFGLEDPEDD  
ICKYDFVEVEEPSDGTILGRWCGSGTVPKGQISKGNQIRIRFVSDEYFPSEPGFCIH  
NIVMPQFTEAVSPSVLPSPALPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYR  
TWQLLGKAFVFGKRKSRVDLNLLEEVRLYSCTPRNFSVSIREELKRTDTIFWPGLL  
VKRCGGNCACCLHNCNECQCVPSKVTKKYHEVLQLRPKTGVRGLHKSLLTDVALEHHEE  
CDCVCRGSTGG"

polyA\_signal

2974..2979

BASE COUNT 858 a 613 c 635 g 901 t



ORIGIN

1 gcccgagag ccgcatttat tggcagcttt gttattgac agaaactgct cgccgccgac  
61 ttggcttcca gtctggctgc gggcaacct tgagttttcg cctctgtcct gtcccccgaa  
121 ctgacaggtg ctccagcaa cttgctgggg acttctcgcc gctccccgc gtccccaccc

```
181 cctcatttct cctcgcctt cccccccacc cccaccactt cgccacagct caggatttgt
241 ttaaactttg ggaaactggg tcaggtccag gttttgcttt gatccttttc aaaaactgga
301 gacacagaag agggctctag gaaaaagttt tggatgggat tatgtggaaa ctaccctgcg
361 attctctgct gccagagcag gctcggcgct tccacccag tgcagccttc ccttggcggt
421 ggtgaaagag actcgggagt cgctgcttcc aaagtgcccg ccgtgagtga gctctcacc
481 cagtcagcca aatgagcctc ttcgggcttc tcctgctgac atctgccctg gccggccaga
541 gacaggggac tcagggcgaa tccaacctga gtagtaaatt ccagtttttc agcaacaagg
601 aacagaacgg agtacaagat cctcagcatg agagaattat tactgtgtct actaatggaa
661 gtattcacag cccaaggttt cctcatactt atccaagaaa tacggctctg gtatggagat
721 tagtagcagt agaggaaaat gtatggatac aacttacgtt tgatgaaaga tttgggcttg
781 aagaccaga agatgacata tgcaagtatg atttttaga agtggaggaa cccagtgatg
841 gaactatatt agggcgctgg tgtggttctg gtactgtacc aggaaaacag atttctaaag
901 gaaatcaaat taggataaga tttgtatctg atgaatat tcttctgtaa ccagggttct
961 gcatccacta caacattgtc atgccacaat tcacagaagc tgtgagtcct tcagtgtctac
1021 ccccttcagc tttgccactg gacctgctta ataagtctat aactgccttt agtacccttg
1081 aagaccttat tcgatatctt gaaccagaga gatggcagtt ggacttagaa gatctatata
1141 ggccaacttg gcaacttctt ggcaaggctt ttgtttttgg aagaaaatcc agagtgggtg
1201 atctgaacct tctaacagag gaggtaagat tatacagctg cacacctcgt aacttctcag
1261 tgtccataag ggaagaacta aagagaaccg ataccatttt ctggccaggt tgtctcctgg
1321 ttaaactgctg tgggtgggaa tgtgctgtt gtctccaca ttgcaatgaa tgtcaatgtg
1381 tcccaagcaa agttactaaa aaataccacg aggtccttca gttgagacca aagaccggtg
1441 tcaggggatt gcacaaatca ctaccgacg tggccctgga gcaccatgag gagtgtgact
1501 gtgtgtgcag agggagcaca ggaggatagc cgcacacca ccagcagctc ttgccagag
1561 ctgtgcagtg cagtggctga ttctattaga gaacgtatgc gttatctcca tcttaactc
1621 cagttgtttg cttcaaggac ctttcatctt caggatttac agtgcattct gaaagaggag
1681 acatcaaaca gaattaggag ttgtgcaaca gctcttttga gaggaggcct aaaggacagg
1741 agaaaagggtc ttcaatcgtg gaaagaaaat taaatgttgt attaaataga tcaccagcta
1801 gtttcagagt taccatgtac gtattccact agctgggttc tgtatttcag ttctttcgat
1861 acgggcttagg gtaatgtcag tacaggaaaa aaactgtgca agtgagcacc tgattccggt
1921 gccttgctta actctaaagc tccatgtcct gggcctaaaa tcgtataaaa tctggatttt
1981 tttttttttt tttgctcata ttacatatg taaaccagaa cattctatgt actacaaacc
2041 tgggtttttta aaaggaacta tgttgctatg aattaaactt gtgtcgtgct gataggacag
2101 actggatttt tcatatttct tattaaatt tctgccattt agaagaagag aactacattc
2161 atgggtttgga agagataaac ctgaaaagaa gagtggcctt atcttcactt tatcgataag
2221 tcagttttatt tgtttcattg tgtacatttt tatattctcc ttttgacatt ataactgttg
2281 gctttttctaa tcttgttaaa tatacttatt ttaccaaaag gtatttaata ttctttttta
2341 tgacaactta gatcaactat ttttagcttg gtaaattttt ctaaacacaa ttgttatagc
2401 cagaggaaca aagatgatat aaaatattgt tgccttgaca aaaatacatg tatttcattc
2461 tcgtatgggtg cttagagttag attaatctgc attttaaaaa actgaattgg aatagaattg
2521 gtaagttgca aagacttttt gaaaataatt aaattatcat atcttcatt cctgttattg
2581 gagatgaaaa taaaagcaa cttatgaaag tagacattca gatccagcca ttactaacct
2641 attccttttt tggggaaatc tgagcctagc tcagaaaaac ataaagcacc ttgaaaaaga
2701 cttggcagct tcctgataaa gcgtgctgtg ctgtgcagta ggaacacatc ctatttattg
2761 tgatgtttgtg gttttattat cttaaactct gttccatata cttgtataaa tacatggata
2821 tttttatgta cagaagtatg tctcttaacc agttcactta ttgtactctg gcaatttaaa
2881 agaaaatcag taaaatattt tgcttgtaaa atgcttaata tcgtgcctag gttatgtggt
2941 gactatttga atcaaaaatg tattgaatca tcaataaaaa gaatgtggct attttgggga
3001 gaaaatt
```

Revised: July 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Bc

Search PubMed for [ ] Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: FEBS Lett 2000 Jun 16;475(2):97-102

Related Articles, Link

ELSEVIER SCIENCE  
FULL-TEXT ARTICLE

**A novel gene derived from developing spinal cords, SCDGF, is a unique member of the PDGF/VEGF family.**

**Hamada T, Ui-Tei K, Miyata Y.**

Department of Pharmacology, Nippon Medical School, Tokyo, Japan.

We isolated a novel gene designated spinal cord-derived growth factor (SCDGF). Its expression was increased in chick spinal cords with embryonic development and decreased after hatching. The amino acid sequences of chick and human SCDGFs revealed a putative signal sequence followed by a CUB domain and a region homologous to the members of the platelet-derived growth factor/vascular endothelial growth factor family. Furthermore, human SCDGF secreted from the cells showed a mitogenic activity for 10T1/2 cells in vitro. These results led us to speculate that SCDGF plays an important role in the development of the spinal cord.

PMID: 10858496 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

Mar 3 2003 10:01:4



>AB033831 ACCESSION:AB033831 NID: gi 9392293 dbj AB033831.1 Homo  
sapiens hSCDGF mRNA for spinal cord-derived growth  
factor, complete cds  
Length = 1817


Score = 486 bits (1237), Expect = e-135  
Identities = 234/234 (100%), Positives = 234/234 (100%)  
Frame = +3

Query: 1 MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 60  
MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS  
Sbjct: 327 MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHS 506

Query: 61 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 120  
PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL  
Sbjct: 507 PRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTIL 686

Query: 121 GRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 180  
GRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA  
Sbjct: 687 GRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPSSA 866

Query: 181 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGRKSR 234  
LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGRKSR  
Sbjct: 867 LPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGRKSR 1028



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Boo

Search  for 

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show: 

Send to

Get Subsequence

☐ 1: AB033831. Homo sapiens hSCD...[gi:9392293]

Links

LOCUS AB033831 1817 bp mRNA linear PRI 26-JUL-2000  
 DEFINITION Homo sapiens hSCDGF mRNA for spinal cord-derived growth factor,  
 complete cds.

ACCESSION AB033831

VERSION AB033831.1 GI:9392293

KEYWORDS spinal cord-derived growth factor; scdgm gene.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (sites)

AUTHORS Hamada,T., Ui-Tei,K. and Miyata,Y.

TITLE A novel gene derived from developing spinal cords, SCDGF, is a  
 unique member of the PDGF/VEGF family

JOURNAL FEBS Lett. 475 (2), 97-102 (2000)

MEDLINE 20317014

PUBMED 10858496

REFERENCE 2 (bases 1 to 1817)

AUTHORS Hamada,T., Ui-Tei,K. and Miyata,Y.

TITLE Direct Submission

JOURNAL Submitted (25-OCT-1999) Tsuyoshi Hamada, Nippon Medical School,  
 Department of Pharmacology; 1-1-5, Sendagi, Bunkyo-ku, Tokyo  
 113-8602, Japan (E-mail:t-hamada@nms.ac.jp,  
 Tel:81-3-3822-2131(ex.5277), Fax:81-3-5814-1684)

FEATURES

Location/Qualifiers

source

1..1817

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/tissue\_type="brain"

/dev\_stage="embryo"

gene

1..1817

/gene="hSCDGF"

CDS

327..1364

/gene="hSCDGF"

/codon\_start=1

/product="spinal cord-derived growth factor"

/protein\_id="BAB03266.1"

/db\_xref="GI:9392294"

/translation="MSLFGLLLLSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDP  
 QHERIITVSTNGSIHSPRPHTYPRNTVLVWRLVAEENVWIQLTFDERFGLEDPEDD  
 ICKYDFVEVEEPSDGTILGRWCGSGTVPKGQISKGNQIRIRFVSDEYFPSEPGFCIH  
 NIVMPQFTEAVSPSVLPPSALPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRP  
 TWQLLGKAFVFGKSRVVDLNLLEEVRLYSCTPRNFSVSIREELKRTDTIFWPGCLL  
 VKRCGGNCACCLHNCNECQCVPKVKYHEVLQLRPKTGVRGLHKSLLTDVALEHHEE  
 CDCVCRGSTGG"

BASE COUNT  
 ORIGIN

501 a 412 c 424 g 477 t 3 others

```
1  cccgcntncc caccacctca ttctccctc gccttcaccc ccacccccac cacttcgnca
61  cagctcagga tttgtttaaa ccttgggaaa ctgggttcagg tccaggtttt gctttgatcc
121 ttttcaaaaa ctggagacac agaagagggc tctaggaaaa agttttggat gggattatgt
181 ggaaactacc ctgcgattct ctgctgccag agcaggctcg gcgcttcac cccagtgcag
241 ccttcccctg gcggtggtga aagagactcg ggagtcgctg cttccaaagt gcccgccgtg
301 agtgagctct caccaccagtc agccaaatga gcctcttcgg gcttctcctg ctgacatctg
361 ccctggccgg ccagagacag gggactcagg cggaatccaa cctgagtagt aaattccagt
421 tttccagcaa caaggaacag aacggagtac aagatcctca gcatgagaga attattactg
481 tgtctactaa tggaagtatt cacagcccaa ggtttcctca tacttatcca agaaatacgg
541 tcttggtatg gagattagta gcagtagagg aaaatgtatg gatacaactt acgtttgatg
601 aaagatttgg gcttgaagac ccagaagatg acatatgcaa gtafgatttt gtagaagttg
661 aggaacccag tgatggaact atattagggc gctgggtggtg ttctgggtact gtaccaggaa
721 aacagatttc taaaggaaat caaattagga taagatttgt atctgatgaa tattttcctt
781 ctgaaccagg gttctgcac cactacaaca ttgtcatgcc acaattcaca gaagctgtga
841 gtccttcagt gctacccctc tcagctttgc cactggacct gcttaataat gctataactg
901 ccttttagtac cttggaagac cttattcgat atcttgaacc agagagatgg cagttggact
961 tagaagatct atataggcca acttggcaac ttcttggcaa ggcttttgtt tttggaagaa
1021 aatccagagt ggtggatctg aaccttctaa cagaggaggt aagattatac agctgcacac
1081 ctgtaactt ctcagtgtcc ataagggaag aactaaagag aaccgatacc attttctggc
1141 caggttgtct cctggttaaa cgctgtggtg ggaactgtgc ctgttgctc cacaattgca
1201 atgaatgtca atgtgtccca agcaaagtta ctaaaaaata ccacgaggtc cttcagttga
1261 gaccaaagac cgggtgtcagg ggattgcaca aatcactcac cgacgtggcc ctggagcacc
1321 atgaggagtg tgactgtgtg tgcagaggga gcacaggagg atagccgcat caccaccagc
1381 agctcttgcc caaagctgtg cagtgcagtg gctgattcta ttaaagaacg tatgcgttat
1441 ctccatcctt aatctcagtt gtttgcttca aggacctttc atcttcagga tttacagtgc
1501 attctgaaag aggagacatc aaacagaatt aggagtgtg caacagctct tttgagagga
1561 ggcctaaagg acaggagaaa aggtcttcaa tcgtggaaag aaaattaaat gttgtattaa
1621 atagatcacc agctagtttc agagttacca tggtacgtat tccactagct gggttctgta
1681 tttcagttct ttcgatacag cttagggtta tagtcagtac aggcaaaaaa tactgtgcag
1741 agtgatcacc tgattccggt gccttgctta actctaaagc tccatgtcct gggcctaaaa
1801 tcgtataaaa tctggat
```

//

Revised: July 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLN](#) | [NIH](#)

Mar 3 2003 10:13:39



Query= SEQ ID NO:6  
(918 letters)

Sequences producing significant alignments:

Score E  
(bits) Value

AC092608.2.1.196952

430 e-118

AC093325.3.1.130754

236 2e-59

>AC092608.2.1.196952

Length = 196952

Score = 430 bits (217), Expect = e-118

Identities = 217/217 (100%)

Strand = Plus / Minus

Query: 702 aggagataattatgaaaaggaaaaaaatctgaagaccaacttttacaaatatttggcaga 761  
|||||  
Sbjct: 74905 aggagataattatgaaaaggaaaaaaatctgaagaccaacttttacaaatatttggcaga 74846

Query: 762 gggaaacttctttaatattattatagttaagctattcaaaaagtatcctttggtacatta 821  
|||||  
Sbjct: 74845 gggaaacttctttaatattattatagttaagctattcaaaaagtatcctttggtacatta 74786

Query: 822 tctttctttcttcttttcttttcttttatttgccttcccccccaaaagtactatac 881  
|||||  
Sbjct: 74785 tctttctttcttcttttcttttcttttatttgccttcccccccaaaagtactatac 74726

Query: 882 aatgtttcaagaatgtatgacatatgacttaacttaa 918  
|||||  
Sbjct: 74725 aatgtttcaagaatgtatgacatatgacttaacttaa 74689

Score = 414 bits (209), Expect = e-113

Identities = 209/209 (100%)

Strand = Plus / Minus

Query: 496 caattcacagaagctgtgagtccttcagtgtaccccccttcagctttgccactggacctg 555  
|||||  
Sbjct: 77153 caattcacagaagctgtgagtccttcagtgtaccccccttcagctttgccactggacctg 77094

Query: 556 cttaataatgctataactgccttttagtaccttggaagaccttattcgatatcttgaacca 615  
|||||  
Sbjct: 77093 cttaataatgctataactgccttttagtaccttggaagaccttattcgatatcttgaacca 77034

Query: 616 gagagatggcagttggacttagaagatctatataggccaacttggcaacttcttggcaag 675  
|||||  
Sbjct: 77033 gagagatggcagttggacttagaagatctatataggccaacttggcaacttcttggcaag 76974



Query: 676 gcttttgtttttggaagaaaatccagagg 704  
|||||  
Sbjct: 76973 gcttttgtttttggaagaaaatccagagg 76945

Score = 396 bits (200), Expect = e-108  
Identities = 200/200 (100%)  
Strand = Plus / Minus

Query: 118 ggagtacaagatcctcagcatgagagaattattactgtgtctactaatggaagtattcac 177  
|||||  
Sbjct: 154677 ggagtacaagatcctcagcatgagagaattattactgtgtctactaatggaagtattcac 154618

Query: 178 agcccaagggtttcctcatacttatccaagaaatacggctcttggtatggagattagtagca 237  
|||||  
Sbjct: 154617 agcccaagggtttcctcatacttatccaagaaatacggctcttggtatggagattagtagca 154558

Query: 238 gtagaggaaaatgtatggatacaacttacgtttgatgaaagatttgggcttgaagaccca 297  
|||||  
Sbjct: 154557 gtagaggaaaatgtatggatacaacttacgtttgatgaaagatttgggcttgaagaccca 154498

Query: 298 gaagatgacatatgcaagta 317  
|||||  
Sbjct: 154497 gaagatgacatatgcaagta 154478

Score = 361 bits (182), Expect = 5e-97  
Identities = 185/186 (99%)  
Strand = Plus / Minus

Query: 310 tgcaagtatgattttgtagaagttgaggaacccagtgatggaactatattagggcgctgg 369  
|||||  
Sbjct: 115282 tgcaggtatgattttgtagaagttgaggaacccagtgatggaactatattagggcgctgg 115223

Query: 370 tgtggttctggtactgtaccaggaaaacagatttctaaaggaaatcaaattaggataaga 429  
|||||  
Sbjct: 115222 tgtggttctggtactgtaccaggaaaacagatttctaaaggaaatcaaattaggataaga 115163

Query: 430 tttgtatctgatgaatattttcttctgaaccagggttctgcacccactacaacattgtc 489  
|||||  
Sbjct: 115162 tttgtatctgatgaatattttcttctgaaccagggttctgcacccactacaacattgtc 115103



Query: 490 atgcca 495  
|||||  
Sbjct: 115102 atgcca 115097

>AC093325.3.1.130754  
Length = 130754

Score = 236 bits (119), Expect = 2e-59  
Identities = 119/119 (100%)  
Strand = Plus / Minus

```
Query: 1      atgagcctcttcgggcttctcctgctgacatctgccctggccggccagagacaggggact 60
              |||
Sbjct: 80211  atgagcctcttcgggcttctcctgctgacatctgccctggccggccagagacaggggact 80152

Query: 61      caggcggaatccaacctgagtagtaaattccagttttccagcaacaaggaacagaacgg 119
              |||
Sbjct: 80151  caggcggaatccaacctgagtagtaaattccagttttccagcaacaaggaacagaacgg 80093
```



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Boo

Search  for 

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

default

Show: 20

Send to


File

Get Subsequence

1: AC092608. Homo sapiens BAC ...[gi:15668121]

Links

LOCUS AC092608 196952 bp DNA linear PRI 01-MAR-2002  
 DEFINITION Homo sapiens BAC clone RP11-154F14 from 4, complete sequence.  
 ACCESSION AC092608 AC009582  
 VERSION AC092608.2 GI:15668121  
 KEYWORDS HTG.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 196952)  
 AUTHORS Sulston, J.E. and Waterston, R.  
 TITLE Toward a complete human genome sequence  
 JOURNAL Genome Res. 8 (11), 1097-1108 (1998)  
 MEDLINE 99063792  
 PUBMED 9847074  
 REFERENCE 2 (bases 1 to 196952)  
 AUTHORS Isak, A., Kozlowicz, A. and Hawkins, M.  
 TITLE The sequence of Homo sapiens BAC clone RP11-154F14  
 JOURNAL Unpublished (2001)  
 REFERENCE 3 (bases 1 to 196952)  
 AUTHORS Waterston, R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (19-JUL-2001) Genome Sequencing Center, Washington  
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,  
 MO 63108, USA  
 REFERENCE 4 (bases 1 to 196952)  
 AUTHORS Waterston, R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (19-SEP-2001) Genome Sequencing Center, Washington  
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,  
 MO 63108, USA  
 REFERENCE 5 (bases 1 to 196952)  
 AUTHORS Waterston, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (01-MAR-2002) Department of Genetics, Washington  
 University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA  
 COMMENT On Sep 19, 2001 this sequence version replaced gi:14916193.  
 ----- Genome Center  
 Center: Washington University Genome Sequencing Center  
 Center code: WUGSC  
 Web site: <http://genome.wustl.edu/gsc>  
 Contact: [sapiens@watson.wustl.edu](mailto:sapiens@watson.wustl.edu)  
 ----- Summary Statistics  
 Center project name: H\_NH0154F14  
 Drafting Center: WIBR  
 -----



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Boo

Search  for 

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

default

Show:

20

Send to

File

Get Subsequence

1: AC093325. Homo sapiens BAC ...[gi:15982602]

Links

LOCUS AC093325 130754 bp DNA linear PRI 09-JAN-2002  
 DEFINITION Homo sapiens BAC clone RP11-612J15 from 4, complete sequence.  
 ACCESSION AC093325  
 VERSION AC093325.3 GI:15982602  
 KEYWORDS HTG.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 130754)  
 AUTHORS Sulston, J.E. and Waterston, R.  
 TITLE Toward a complete human genome sequence  
 JOURNAL Genome Res. 8 (11), 1097-1108 (1998)  
 MEDLINE 99063792  
 PUBMED 9847074

REFERENCE 2 (bases 1 to 130754)  
 AUTHORS Waligorski, J. and Haakenson, W.  
 TITLE The sequence of Homo sapiens BAC clone RP11-612J15  
 JOURNAL Unpublished (2002)

REFERENCE 3 (bases 1 to 130754)  
 AUTHORS Waterston, R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (18-AUG-2001) Genome Sequencing Center, Washington  
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,  
 MO 63108, USA

REFERENCE 4 (bases 1 to 130754)  
 AUTHORS Waterston, R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (07-OCT-2001) Genome Sequencing Center, Washington  
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,  
 MO 63108, USA

REFERENCE 5 (bases 1 to 130754)  
 AUTHORS Waterston, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (09-JAN-2002) Department of Genetics, Washington  
 University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA

COMMENT On Oct 7, 2001 this sequence version replaced gi:15624997.  
 ----- Genome Center  
 Center: Washington University Genome Sequencing Center  
 Center code: WUGSC  
 Web site: <http://genome.wustl.edu/gsc>  
 Contact: sapiens@watson.wustl.edu  
 ----- Summary Statistics  
 Center project name: H\_NH0612J15  
 -----

NOTICE: This sequence may not represent the entire insert of this